

EML4-ALK Mutations in Lung Cancer That Confer Resis

New England Journal of Medicine

363, 1734-1739

DOI: [10.1056/nejmoa1007478](https://doi.org/10.1056/nejmoa1007478)

Citation Report

#	ARTICLE	IF	CITATIONS
1	The Genomics of Lung Adenocarcinoma: Opportunities for Targeted Therapies. <i>Genes and Cancer</i> , 2010, 1, 1200-1210.	0.6	88
2	ALK Inhibition for Non-Small Cell Lung Cancer: From Discovery to Therapy in Record Time. <i>Cancer Cell</i> , 2010, 18, 548-551.	7.7	211
3	ALK and resistance. <i>Nature Reviews Cancer</i> , 2010, 10, 817-817.	12.8	2
4	Success for crizotinib in ALK-driven cancer. <i>Nature Reviews Drug Discovery</i> , 2010, 9, 908-908.	21.5	4
5	Crizotinib â€” Latest Champion in the Cancer Wars?. <i>New England Journal of Medicine</i> , 2010, 363, 1760-1762.	13.9	65
6	Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 1677-1687.	1.1	29
7	Iron as a target of chemoprevention for longevity in humans. <i>Free Radical Research</i> , 2011, 45, 906-917.	1.5	49
8	Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 7535-7540.	3.3	515
9	The Neuroblastoma ALK(I1250T) Mutation Is a Kinase-Dead RTK In Vitro and In Vivo. <i>Translational Oncology</i> , 2011, 4, 258-IN6.	1.7	27
10	A Decade of Advances in Treatment for Advanced Nonâ€”Small Cell Lung Cancer. <i>Clinics in Chest Medicine</i> , 2011, 32, 839-851.	0.8	58
11	Identification of Oncogenic Point Mutations and Hyperphosphorylation of Anaplastic Lymphoma Kinase in Lung Cancer. <i>Neoplasia</i> , 2011, 13, 704-IN24.	2.3	41
12	Cancer: Beyond Speciation. <i>Advances in Cancer Research</i> , 2011, 112, 283-350.	1.9	60
13	One size does not fit all. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 68-70.	12.5	48
14	Do all lung adenocarcinomas follow a stepwise progression?. <i>Lung Cancer</i> , 2011, 74, 7-11.	0.9	110
15	Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged nonsmall cell lung cancer and beyond. <i>Drug Design, Development and Therapy</i> , 2011, 5, 471.	2.0	165
16	Personalized medicine in lung cancer: what we need to know. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 661-668.	12.5	145
17	Role of Genotyping in Non-Small Cell Lung Cancer Treatment. <i>Drugs</i> , 2011, 71, 2231-2246.	4.9	23
18	The potential for crizotinib in non-small cell lung cancer: a perspective review. <i>Therapeutic Advances in Medical Oncology</i> , 2011, 3, 279-291.	1.4	72

#	ARTICLE	IF	CITATIONS
19	Insights into ALK-Driven Cancers Revealed through Development of Novel ALK Tyrosine Kinase Inhibitors. <i>Cancer Research</i> , 2011, 71, 4920-4931.	0.4	203
22	Crizotinib. <i>Nature Reviews Drug Discovery</i> , 2011, 10, 897-898.	21.5	106
23	New targeted therapies for gastric cancer. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 595-604.	1.9	20
25	Basic science of lung cancer. <i>European Journal of Cancer</i> , 2011, 47, S319-S321.	1.3	2
26	Discovery of 3,5-Diamino-1,2,4-triazole Ureas as Potent Anaplastic Lymphoma Kinase Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2011, 2, 379-384.	1.3	29
27	2,7-Disubstituted-pyrrolo[2,1- <i>f</i>][1,2,4]triazines: New Variant of an Old Template and Application to the Discovery of Anaplastic Lymphoma Kinase (ALK) Inhibitors with in Vivo Antitumor Activity. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 6328-6341.	2.9	40
28	Genetic determinants of anticancer drug activity: towards a global approach to personalized cancer medicine. <i>Expert Review of Molecular Diagnostics</i> , 2011, 11, 567-577.	1.5	6
29	Resistance to Cancer Treatment: The Role of Somatic Genetic Events and the Challenges for Targeted Therapies. <i>Frontiers in Pharmacology</i> , 2011, 2, 59.	1.6	19
30	Novel Oncology Drug Development Strategies in the Era of Personalised Medicine. , 0, , .		0
31	Molecular Biology and Genetics of Lung Cancer. <i>Medical Radiology</i> , 2011, , 3-15.	0.0	2
33	Oncogenic tyrosine kinase NPM-ALK induces expression of the growth-promoting receptor ICOS. <i>Blood</i> , 2011, 118, 3062-3071.	0.6	32
36	Favorable response to crizotinib in three patients with echinoderm microtubule-associated protein-like 4 "anaplastic lymphoma kinase fusion" type oncogene-positive non-small cell lung cancer. <i>Cancer Science</i> , 2011, 102, 1602-1604.	1.7	10
37	Crizotinib-Resistant Mutants of EML4-ALK Identified Through an Accelerated Mutagenesis Screen. <i>Chemical Biology and Drug Design</i> , 2011, 78, 999-1005.	1.5	127
38	Taming the dragon: genomic biomarkers to individualize the treatment of cancer. <i>Nature Medicine</i> , 2011, 17, 304-312.	15.2	94
39	Emerging importance of ALK in neuroblastoma. <i>Seminars in Cancer Biology</i> , 2011, 21, 267-275.	4.3	105
40	Inhibition of N-linked glycosylation impairs ALK phosphorylation and disrupts pro-survival signaling in neuroblastoma cell lines. <i>BMC Cancer</i> , 2011, 11, 525.	1.1	39
41	CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant. <i>Cancer Cell</i> , 2011, 19, 679-690.	7.7	560
42	A General Framework for Inhibitor Resistance in Protein Kinases. <i>Chemistry and Biology</i> , 2011, 18, 966-975.	6.2	49

#	ARTICLE	IF	CITATIONS
43	Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive. Expert Review of Respiratory Medicine, 2011, 5, 413-424.	1.0	24
44	Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling. Journal of Clinical Oncology, 2011, 29, 3085-3096.	0.8	890
46	Treatment for ALK-mutated non-small-cell lung cancer: a new miracle in the research race. Clinical and Translational Oncology, 2011, 13, 774-779.	1.2	3
47	Targetable "Driver" Mutations in Non Small Cell Lung Cancer. Indian Journal of Surgical Oncology, 2011, 2, 178-188.	0.3	22
48	Update in Lung Cancer and Oncological Disorders 2010. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 297-302.	2.5	6
49	Crizotinib: an anaplastic lymphoma kinase inhibitor. Future Oncology, 2011, 7, 947-953.	1.1	17
50	Inhibition of Rac controls NPM"ALK-dependent lymphoma development and dissemination. Blood Cancer Journal, 2011, 1, e21-e21.	2.8	25
51	Selective Therapeutic Targeting of the Anaplastic Lymphoma Kinase With Liposomal siRNA Induces Apoptosis and Inhibits Angiogenesis in Neuroblastoma. Molecular Therapy, 2011, 19, 2201-2212.	3.7	57
52	Con: The Case for Expanded Lung Cancer Research Support. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 1234-1236.	2.5	1
53	Targeted Therapies for Lung Cancer. Cancer Journal (Sudbury, Mass), 2011, 17, 512-527.	1.0	91
54	Clinical Features and Outcome of Patients With Non"Small-Cell Lung Cancer Harboring <i>BRAF</i> Mutations. Journal of Clinical Oncology, 2011, 29, 3574-3579.	0.8	500
55	Targeting Anaplastic Lymphoma Kinase in Lung Cancer. Clinical Cancer Research, 2011, 17, 2081-2086.	3.2	282
56	New Strategies for Treatment of <i>ALK</i>-Rearranged Non"Small Cell Lung Cancers. Clinical Cancer Research, 2011, 17, 7213-7218.	3.2	82
57	A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors. Cancer Research, 2011, 71, 6051-6060.	0.4	560
58	A new frontier in personalized cancer therapy: mapping molecular changes. Future Oncology, 2011, 7, 873-894.	1.1	12
59	Novel Therapeutic Options in Anaplastic Large Cell Lymphoma: Molecular Targets and Immunological Tools. Molecular Cancer Therapeutics, 2011, 10, 1127-1136.	1.9	27
60	CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib. Journal of Clinical Oncology, 2011, 29, e443-e445.	0.8	546
61	Next Generation Radiologic-Pathologic Correlation in Oncology: Rad-Path 2.0. American Journal of Roentgenology, 2011, 197, 990-997.	1.0	29

#	ARTICLE	IF	CITATIONS
62	Hedgehog signaling and therapeutics in pancreatic cancer. <i>Carcinogenesis</i> , 2011, 32, 445-451.	1.3	111
63	Reply to A.H. Fischer et al. <i>Journal of Clinical Oncology</i> , 2011, 29, 3332-3333.	0.8	16
64	Hedgehog Fights Back: Mechanisms of Acquired Resistance against Smoothed Antagonists. <i>Cancer Research</i> , 2011, 71, 5057-5061.	0.4	151
65	Targeting Oncogenic ALK: A Promising Strategy for Cancer Treatment. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 569-579.	1.9	99
66	CRKL as a Lung Cancer Oncogene and Mediator of Acquired Resistance to EGFR Inhibitors: Is It All That It Is Cracked Up to Be?. <i>Cancer Discovery</i> , 2011, 1, 560-561.	7.7	5
67	International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2011, 6, 244-285.	0.5	4,127
68	Differential Inhibitor Sensitivity of Anaplastic Lymphoma Kinase Variants Found in Neuroblastoma. <i>Science Translational Medicine</i> , 2011, 3, 108ra114.	5.8	199
69	The therapeutic potential of anaplastic lymphoma kinase inhibitors in lung cancer: rationale and clinical evidence. <i>Clinical Investigation</i> , 2011, 1, 1119-1126.	0.0	19
70	ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors. <i>Clinical Cancer Research</i> , 2011, 17, 7394-7401.	3.2	179
71	Hypoxia-microRNA-16 downregulation induces VEGF expression in anaplastic lymphoma kinase (ALK)-positive anaplastic large-cell lymphomas. <i>Leukemia</i> , 2011, 25, 1882-1890.	3.3	115
73	More on Crizotinib. <i>New England Journal of Medicine</i> , 2011, 364, 776-779.	13.9	28
74	Sputum-Based Molecular Biomarkers for the Early Detection of Lung Cancer: Limitations and Promise. <i>Cancers</i> , 2011, 3, 2975-2989.	1.7	12
75	Third CECOG consensus on the systemic treatment of non-small-cell lung cancer. <i>Annals of Oncology</i> , 2012, 23, 1223-1229.	0.6	26
76	Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants. <i>Clinical Cancer Research</i> , 2012, 18, 4682-4690.	3.2	252
77	Oncogenic MAP2K1 mutations in human epithelial tumors. <i>Carcinogenesis</i> , 2012, 33, 956-961.	1.3	38
79	Treatment of ALK-Positive Non-Small Cell Lung Cancer. <i>Archives of Pathology and Laboratory Medicine</i> , 2012, 136, 1201-1204.	1.2	31
80	Anaplastic lymphoma kinase (ALK) inhibitors for second-line therapy of non-small cell lung cancer. <i>Lung Cancer: Targets and Therapy</i> , 2012, 3, 91.	1.3	2
81	Anaplastic Lymphoma Kinase Aberrations in Rhabdomyosarcoma: Clinical and Prognostic Implications. <i>Journal of Clinical Oncology</i> , 2012, 30, 308-315.	0.8	108

#	ARTICLE	IF	CITATIONS
82	Personalized Targeted Therapy for Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2012, 13, 11471-11496.	1.8	61
83	Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in <i>EGFR</i>-Mutant Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 2149-2157.	1.9	81
84	Mechanisms of Resistance to Crizotinib in Patients with <i>ALK</i> Gene Rearranged Nonâ€“Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 1472-1482.	3.2	1,018
87	Remarkable Tumor Response to Crizotinib in a 14-Year-Old Girl With ALK-Positive Nonâ€“Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, e147-e150.	0.8	47
88	Cancer Genes in Lung Cancer: Racial Disparities: Are There Any?. <i>Genes and Cancer</i> , 2012, 3, 467-480.	0.6	116
89	Paracrine Receptor Activation by Microenvironment Triggers Bypass Survival Signals and ALK Inhibitor Resistance in EML4-ALK Lung Cancer Cells. <i>Clinical Cancer Research</i> , 2012, 18, 3592-3602.	3.2	104
90	Aberrations and Therapeutics Involving the Developmental Pathway Hedgehog in Pancreatic cancer. <i>Vitamins and Hormones</i> , 2012, 88, 355-378.	0.7	5
91	Repeat Biopsy for Mutational Analysis of Nonâ€“Small Cell Lung Cancers Resistant to Previous Chemotherapy: Adequacy and Complications. <i>Radiology</i> , 2012, 265, 939-948.	3.6	98
92	Targeted Therapy at the End of Life in Advanced Cancer Patients. <i>Journal of Palliative Medicine</i> , 2012, 15, 991-997.	0.6	20
93	Intratumoral Molecular Heterogeneity in a <i>BRAF</i>-Mutant, BRAF Inhibitor-Resistant Melanoma: A Case Illustrating the Challenges for Personalized Medicine. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 2704-2708.	1.9	78
94	Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma. <i>Oncogene</i> , 2012, 31, 4859-4867.	2.6	61
95	New developments in the treatment of ALK-driven malignancies. <i>Clinical Investigation</i> , 2012, 2, 835-852.	0.0	1
96	Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALKâ€“Positive Nonâ€“Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 6219-6226.	3.2	148
97	Isolated central nervous system progression on Crizotinib. <i>Cancer Biology and Therapy</i> , 2012, 13, 1376-1383.	1.5	93
98	CEP-28122, a Highly Potent and Selective Orally Active Inhibitor of Anaplastic Lymphoma Kinase with Antitumor Activity in Experimental Models of Human Cancers. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 670-679.	1.9	66
99	The emerging role of ALK inhibitors in the treatment of advanced non-small cell lung cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, S45-S54.	1.5	17
100	Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers. <i>Science Translational Medicine</i> , 2012, 4, 120ra17.	5.8	1,138
101	Evaluating Translocation Gene Fusions by SNP Array Data. <i>Cancer Informatics</i> , 2012, 11, CIN.S8026.	0.9	6

#	ARTICLE	IF	CITATIONS
102	Proof of Concept to Clinical Confirmation: Evolving Clinical Trial Designs for Targeted Agents. <i>ISRN Oncology</i> , 2012, 2012, 1-6.	2.1	0
103	Molecular Markers with Predictive and Prognostic Relevance in Lung Cancer. <i>Lung Cancer International</i> , 2012, 2012, 1-12.	1.2	17
104	Escaping ALK Inhibition: Mechanisms of and Strategies to Overcome Resistance. <i>Science Translational Medicine</i> , 2012, 4, 120ps2.	5.8	91
105	Anaplastic lymphoma kinase-directed therapy in inflammatory myofibroblastic tumors. <i>Current Opinion in Oncology</i> , 2012, 24, 409-413.	1.1	70
106	Direct serum and tissue assay for EGFR mutation in non-small cell lung cancer by high-resolution melting analysis. <i>Oncology Reports</i> , 2012, 28, 1815-1821.	1.2	40
107	Molecular Characterization by Immunocytochemistry of Lung Adenocarcinoma on Cytology Specimens. <i>Acta Cytologica</i> , 2012, 56, 603-610.	0.7	25
108	Therapeutic Additions and Possible Deletions in Oncology in 2011. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 91, 15-17.	2.3	8
109	Targeted therapy in non-small cell lung cancer. <i>Breathe</i> , 2012, 8, 206-215.	0.6	6
110	Challenges in the codevelopment of companion diagnostics. <i>Personalized Medicine</i> , 2012, 9, 485-496.	0.8	13
111	Crizotinib for the treatment of non-small-cell lung cancer with ALK gene rearrangements. <i>Clinical Investigation</i> , 2012, 2, 895-907.	0.0	1
112	Non-Small Cell Lung Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 1236-1271.	2.3	312
113	Gene fusions in non-small-cell lung cancer. <i>Lung Cancer Management</i> , 2012, 1, 283-292.	1.5	1
114	Acquired Resistance to the ALK Inhibitor Crizotinib in the Absence of an ALK Mutation. <i>Journal of Thoracic Oncology</i> , 2012, 7, 623-625.	0.5	11
115	Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. <i>Lancet Oncology</i> , The, 2012, 13, 1011-1019.	5.1	1,176
116	Crizotinib for the Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: A Success Story to Usher in the Second Decade of Molecular Targeted Therapy in Oncology. <i>Oncologist</i> , 2012, 17, 1351-1375.	1.9	206
117	Crizotinib for ALK-Rearranged Non-Small Cell Lung Cancer: A New Targeted Therapy for a New Target. <i>Clinical Cancer Research</i> , 2012, 18, 3737-3742.	3.2	82
118	Mechanisms of intrinsic and acquired resistance to kinase-targeted therapies. <i>Pigment Cell and Melanoma Research</i> , 2012, 25, 819-831.	1.5	43
119	Anaplastic lymphoma kinase as a therapeutic target. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, 1127-1138.	1.5	27

#	ARTICLE	IF	CITATIONS
120	Integrated analysis of genetic and epigenetic alterations reveals CpG island methylator phenotype associated with distinct clinical characters of lung adenocarcinoma. <i>Carcinogenesis</i> , 2012, 33, 1277-1285.	1.3	57
121	PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas. <i>Nature Medicine</i> , 2012, 18, 1699-1704.	15.2	113
122	Lung Cancer Genotype-Based Therapy and Predictive Biomarkers: Present and Future. <i>Archives of Pathology and Laboratory Medicine</i> , 2012, 136, 1482-1491.	1.2	40
124	Directed Therapies in Lung Cancer: New Hope?. <i>Archivos De Bronconeumologia</i> , 2012, 48, 367-371.	0.4	5
125	Terapias dirigidas en el c�ncer de pulm�n: �una nueva esperanza?. <i>Archivos De Bronconeumologia</i> , 2012, 48, 367-371.	0.4	6
126	MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF-� ² Receptor Signaling. <i>Cell</i> , 2012, 151, 937-950.	13.5	371
128	Targeted therapy for NSCLC: ALK inhibition. <i>Journal of Oncology Pharmacy Practice</i> , 2012, 18, 271-274.	0.5	7
129	The battle against ALK resistance: successes and setbacks. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 1751-1754.	1.9	15
130	Targeted therapy in rare cancers��adopting the orphans. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 631-642.	12.5	39
131	MicroRNA 96 Is a Post-Transcriptional Suppressor of Anaplastic Lymphoma Kinase Expression. <i>American Journal of Pathology</i> , 2012, 180, 1772-1780.	1.9	45
132	A molecular dynamics investigation on the crizotinib resistance mechanism of C1156Y mutation in ALK. <i>Biochemical and Biophysical Research Communications</i> , 2012, 423, 319-324.	1.0	58
133	Converting Cancer Therapies into Cures: Lessons from Infectious Diseases. <i>Cell</i> , 2012, 148, 1089-1098.	13.5	159
134	Recent advances in pathway-targeted cancer drug therapies emerging from cancer genome analysis. <i>Current Opinion in Genetics and Development</i> , 2012, 22, 45-49.	1.5	43
135	Crizotinib in the treatment of non-small-cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 1195-1201.	0.9	73
136	Unlocking Pandora's box: personalising cancer cell death in non-small cell lung cancer. <i>EPMA Journal</i> , 2012, 3, 6.	3.3	2
137	ROS1 as a ��druggable�� TM receptor tyrosine kinase: lessons learned from inhibiting the ALK pathway. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 447-456.	1.1	111
138	Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells. <i>Oncogene</i> , 2012, 31, 5193-5200.	2.6	103
139	Genomic biomarkers for patient selection and stratification: the cancer paradigm. <i>Bioanalysis</i> , 2012, 4, 2499-2511.	0.6	8

#	ARTICLE	IF	CITATIONS
140	Pharmacogenetics and pharmacogenomics: role of mutational analysis in anti-cancer targeted therapy. <i>Pharmacogenomics Journal</i> , 2012, 12, 277-286.	0.9	32
141	Apoptosis In Targeted Therapy Responses. <i>Advances in Pharmacology</i> , 2012, 65, 519-542.	1.2	58
142	ALK fusion gene positive lung cancer and 3 cases treated with an inhibitor for ALK kinase activity. <i>Lung Cancer</i> , 2012, 75, 66-72.	0.9	32
143	The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group. <i>Lung Cancer</i> , 2012, 76, 1-18.	0.9	206
144	Histologic subtypes, immunohistochemistry, FISH or molecular screening for the accurate diagnosis of ALK-rearrangement in lung cancer: A comprehensive study of Caucasian non-smokers. <i>Lung Cancer</i> , 2012, 76, 309-315.	0.9	59
145	Biomarkers That Currently Affect Clinical Practice: EGFR, ALK, MET, KRAS. <i>Current Oncology</i> , 2012, 19, 33-44.	0.9	46
146	Anaplastic Lymphoma Kinase Inhibitors for the Treatment of ALK-Positive Cancers. <i>Annual Reports in Medicinal Chemistry</i> , 2012, 47, 281-293.	0.5	12
147	Treating ALK-positive lung cancer—early successes and future challenges. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 268-277.	12.5	224
148	Modeling Oncogenic Signaling Networks from Gene Expression Dynamics. , 2012, , 69-81.		0
149	Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation—diversity, ductility, and destiny. <i>Cancer and Metastasis Reviews</i> , 2012, 31, 807-814.	2.7	132
150	Mechanisms of acquired resistance to targeted cancer therapies. <i>Future Oncology</i> , 2012, 8, 999-1014.	1.1	150
151	Targeted drug development in melanoma and nonsmall cell lung cancer: BRAF, MEK, and ALK inhibitors. <i>Memo - Magazine of European Medical Oncology</i> , 2012, 5, 302-308.	0.3	0
152	Crizotinib: a drug that crystallizes a unique molecular subset of non-small-cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 151-162.	1.1	20
154	The R1275Q Neuroblastoma Mutant and Certain ATP-competitive Inhibitors Stabilize Alternative Activation Loop Conformations of Anaplastic Lymphoma Kinase. <i>Journal of Biological Chemistry</i> , 2012, 287, 37447-37457.	1.6	40
155	Personalized cancer therapy for stage IV non-small cell lung cancer: Combined use of active hexose correlated compound and genistein concentrated polysaccharide. <i>Personalized Medicine Universe</i> , 2012, 1, 39-44.	0.1	5
156	Novel treatment avenues for peripheral T-cell lymphomas. <i>Expert Opinion on Drug Discovery</i> , 2012, 7, 1149-1163.	2.5	4
157	Cancer Epigenetics. <i>Methods in Molecular Biology</i> , 2012, , .	0.4	5
158	Tyrosine Kinase Inhibitors in Lung Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2012, 26, 589-605.	0.9	32

#	ARTICLE	IF	CITATIONS
159	Development and Validation of a Prognostic Gene-Expression Signature for Lung Adenocarcinoma. PLoS ONE, 2012, 7, e44225.	1.1	29
160	Advancing the Responsible Use of Medicines: Applying Levers for Change. SSRN Electronic Journal, 0, , .	0.4	52
162	Molecular Therapeutic Advances in Personalized Therapy of Melanoma and Non-Small Cell Lung Cancer. Journal of Personalized Medicine, 2012, 2, 35-49.	1.1	6
163	ALK Inhibitors, a Pharmaceutical Perspective. Frontiers in Oncology, 2012, 2, 17.	1.3	18
164	Activating Mutations and Targeted Therapy in Cancer. , 0, , .		3
165	Mechanisms of Resistance to Targeted Therapies in Acute Myeloid Leukemia and Chronic Myeloid Leukemia. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 685-689.	1.8	2
166	Select Nutrients in the Uterine Lumen of Sheep and Pigs Affect Conceptus Development. Journal of Reproduction and Development, 2012, 58, 180-188.	0.5	52
167	Promising Therapeutic Targets in Neuroblastoma. Clinical Cancer Research, 2012, 18, 2740-2753.	3.2	166
168	Molecular pathology of lung cancer: key to personalized medicine. Modern Pathology, 2012, 25, 347-369.	2.9	215
169	ALKoma: A Cancer Subtype with a Shared Target. Cancer Discovery, 2012, 2, 495-502.	7.7	160
170	Circumventing Cancer Drug Resistance in the Era of Personalized Medicine. Cancer Discovery, 2012, 2, 214-226.	7.7	419
171	Identification and Optimization of Dual PI3K/mTOR Inhibitors. RSC Drug Discovery Series, 2012, , 206-220.	0.2	1
172	Comparative analyses of overall survival in patients with anaplastic lymphoma kinase- ϵ positive and matched wild-type advanced nonsmall cell lung cancer. Cancer, 2012, 118, 3579-3586.	2.0	49
173	Inhibitors of the anaplastic lymphoma kinase. Expert Opinion on Investigational Drugs, 2012, 21, 985-994.	1.9	51
174	The Discovery and Optimization of a Novel Class of Potent, Selective, and Orally Bioavailable Anaplastic Lymphoma Kinase (ALK) Inhibitors with Potential Utility for the Treatment of Cancer. Journal of Medicinal Chemistry, 2012, 55, 6523-6540.	2.9	43
175	The Biology and Clinical Features of Non-small Cell Lung Cancers with EML4-ALK Translocation. Current Oncology Reports, 2012, 14, 105-110.	1.8	35
176	ALK-Mutated Non-Small-Cell Lung Cancer: A New Strategy for Cancer Treatment. Lung, 2012, 190, 381-388.	1.4	9
177	Treatment-Emergent Mutations in NAE ϵ 2 Confer Resistance to the NEDD8-Activating Enzyme Inhibitor MLN4924. Cancer Cell, 2012, 21, 388-401.	7.7	98

#	ARTICLE	IF	CITATIONS
178	Ligand-triggered resistance to molecular targeted drugs in lung cancer: Roles of hepatocyte growth factor and epidermal growth factor receptor ligands. <i>Cancer Science</i> , 2012, 103, 1189-1194.	1.7	64
179	Echinoderm microtubule-associated protein-like 4 "anaplastic lymphoma kinase" targeted therapy for advanced non-small cell lung cancer: Molecular and clinical aspects. <i>Cancer Science</i> , 2012, 103, 1391-1396.	1.7	15
180	Liquid biopsy: monitoring cancer-genetics in the blood. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 472-484.	12.5	1,482
181	Diagnostic Pathology of Pleuropulmonary Neoplasia. , 2013, , .		8
182	MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib. <i>Molecular Oncology</i> , 2013, 7, 112-120.	2.1	70
183	ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC. <i>Targeted Oncology</i> , 2013, 8, 55-67.	1.7	72
184	Phosphoproteomic analysis of anaplastic lymphoma kinase (<sc>ALK</sc>) downstream signaling pathways identifies signal transducer and activator of transcription 3 as a functional target of activated <sc>ALK</sc> in neuroblastoma cells. <i>FEBS Journal</i> , 2013, 280, 5269-5282.	2.2	35
185	Oncogenic driver mutations in lung cancer. <i>Translational Respiratory Medicine</i> , 2013, 1, 6.	3.8	49
186	The preclinical profile of crizotinib for the treatment of non-small-cell lung cancer and other neoplastic disorders. <i>Expert Opinion on Drug Discovery</i> , 2013, 8, 1165-1179.	2.5	32
187	Insight into Crizotinib Resistance Mechanisms Caused by Three Mutations in ALK Tyrosine Kinase using Free Energy Calculation Approaches. <i>Journal of Chemical Information and Modeling</i> , 2013, 53, 2376-2389.	2.5	85
188	Current status and perspective of EBUS-TBNA. <i>General Thoracic and Cardiovascular Surgery</i> , 2013, 61, 390-396.	0.4	47
189	Structural and Energetic Analyses of SNPs in Drug Targets and Implications for Drug Therapy. <i>Journal of Chemical Information and Modeling</i> , 2013, 53, 3343-3351.	2.5	25
190	The quest to overcome resistance to EGFR-targeted therapies in cancer. <i>Nature Medicine</i> , 2013, 19, 1389-1400.	15.2	883
191	Current Status of Targeted Therapy for Anaplastic Lymphoma Kinase "Rearranged Non-Small Cell Lung Cancer. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 95, 15-23.	2.3	82
192	Epithelial-mesenchymal transition leads to crizotinib resistance in H2228 lung cancer cells with EML4-ALK translocation. <i>Molecular Oncology</i> , 2013, 7, 1093-1102.	2.1	101
193	Novel bis-ortho-alkoxy-para-piperazinesubstituted-2,4-dianilinopyrimidines (KRCA-0008) as potent and selective ALK inhibitors for anticancer treatment. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 6192-6196.	1.0	21
194	Crizotinib in the Treatment of Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2013, 14, 473-480.	1.1	36
195	Mechanisms of resistance to BCR-ABL and other kinase inhibitors. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2013, 1834, 1449-1459.	1.1	51

#	ARTICLE	IF	CITATIONS
196	Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer. <i>Science Translational Medicine</i> , 2013, 5, 216ra177.	5.8	438
197	Micro and Nano Flow Systems for Bioanalysis. , 2013, , .		3
198	A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments. <i>Carcinogenesis</i> , 2013, 34, 725-738.	1.3	86
199	Crizotinib: A Review of Its Use in the Treatment of Anaplastic Lymphoma Kinase-Positive, Advanced Non-Small Cell Lung Cancer. <i>Drugs</i> , 2013, 73, 2031-2051.	4.9	70
200	<i>ALK</i> Rearrangements Are Mutually Exclusive with Mutations in <i>EGFR</i> or <i>KRAS</i> : An Analysis of 1,683 Patients with Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 4273-4281.	3.2	521
201	Akt kinase-interacting protein1, a novel therapeutic target for lung cancer with EGFR-activating and gatekeeper mutations. <i>Oncogene</i> , 2013, 32, 4427-4435.	2.6	23
202	Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology. <i>Nature Reviews Cancer</i> , 2013, 13, 685-700.	12.8	538
203	The ALK translocation in advanced non-small cell lung carcinomas: preapproval testing experience at a single cancer centre. <i>Histopathology</i> , 2013, 62, 609-616.	1.6	16
204	Development of hybrid small molecules that induce degradation of estrogen receptor α and necrotic cell death in breast cancer cells. <i>Cancer Science</i> , 2013, 104, 1492-1498.	1.7	112
205	Anaplastic lymphoma kinase: a glimmer of hope in lung cancer treatment?. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 407-420.	1.1	22
206	Characterization of genetic lesions in rhabdomyosarcoma using a high-density single nucleotide polymorphism array. <i>Cancer Science</i> , 2013, 104, 856-864.	1.7	33
207	Brentuximab vedotin: treatment role for relapsed refractory systemic anaplastic large-cell lymphoma. <i>Expert Review of Hematology</i> , 2013, 6, 361-373.	1.0	6
208	Molecular Pathology of Lung Cancer. , 2013, , 443-459.		0
209	Monoclonal antibodies in lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 209-226.	1.4	17
210	<i>ALK</i> in Lung Cancer: Past, Present, and Future. <i>Journal of Clinical Oncology</i> , 2013, 31, 1105-1111.	0.8	387
211	Mutation de l'EGFR, de l'attitude du gène à la pratique clinique : exemplarité ou exception ?. <i>Revue Des Maladies Respiratoires Actualites</i> , 2013, 5, 519-537.	0.0	1
212	Molecular profiles of non-small cell lung cancers in cigarette smoking and never-smoking patients. <i>Advances in Medical Sciences</i> , 2013, 58, 196-206.	0.9	24
213	ALK as a paradigm of oncogenic promiscuity: different mechanisms of activation and different fusion partners drive tumors of different lineages. <i>Cancer Genetics</i> , 2013, 206, 357-373.	0.2	51

#	ARTICLE	IF	CITATIONS
214	Emerging Paradigms in the Development of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 3987-3996.	0.8	299
215	<i>EGFR</i> and <i>KRAS</i> mutations, and <i>ALK</i> fusions: current developments and personalized therapies for patients with advanced non-small-cell lung cancer. <i>Pharmacogenomics</i> , 2013, 14, 1765-1777.	0.6	38
218	Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib. <i>Lung Cancer</i> , 2013, 81, 328-336.	0.9	49
219	Treatment and detection of ALK-rearranged NSCLC. <i>Lung Cancer</i> , 2013, 81, 145-154.	0.9	30
221	Identification of Novel Anaplastic Lymphoma Kinase (ALK) Inhibitors Using a Common Feature Pharmacophore Model Derived from Known Ligands Crystallized with ALK. <i>Chemical Biology and Drug Design</i> , 2013, 81, 175-184.	1.5	3
222	Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment. <i>Genomics</i> , 2013, 102, 157-162.	1.3	42
224	Anaplastic lymphoma kinase (ALK): Structure, oncogenic activation, and pharmacological inhibition. <i>Pharmacological Research</i> , 2013, 68, 68-94.	3.1	238
225	CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study. <i>Lancet Oncology</i> , The, 2013, 14, 590-598.	5.1	555
226	Identification of driver mutations in lung cancer: first step in personalized cancer. <i>Targeted Oncology</i> , 2013, 8, 3-14.	1.7	26
227	Adapting Clinical Paradigms to the Challenges of Cancer Clonal Evolution. <i>American Journal of Pathology</i> , 2013, 182, 1962-1971.	1.9	40
228	Overcoming acquired resistance to kinase inhibition: The cases of EGFR, ALK and BRAF. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 394-401.	1.0	27
229	Acquired Resistance to Crizotinib from a Mutation in <i>CD74</i> – <i>ROS1</i> . <i>New England Journal of Medicine</i> , 2013, 368, 2395-2401.	13.9	345
230	Biopsies: next-generation biospecimens for tailoring therapy. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 437-450.	12.5	110
231	Discovery of 7-azaindole based anaplastic lymphoma kinase (ALK) inhibitors: Wild type and mutant (L1196M) active compounds with unique binding mode. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 4911-4918.	1.0	18
232	Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors. <i>Journal of Molecular Diagnostics</i> , 2013, 15, 415-453.	1.2	397
233	Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. <i>Archives of Pathology and Laboratory Medicine</i> . 2013. 137. 828-860.	1.2	415
234	Epigenetic therapy in non-small-cell lung cancer: targeting DNA methyltransferases and histone deacetylases. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 1273-1285.	1.4	58
235	PROFiling non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 597-608.	0.9	6

#	ARTICLE	IF	CITATIONS
236	Building a Personalized Medicine Infrastructure at a Major Cancer Center. <i>Journal of Clinical Oncology</i> , 2013, 31, 1849-1857.	0.8	101
237	Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. <i>Journal of Thoracic Oncology</i> , 2013, 8, 823-859.	0.5	792
238	Advances in personalized therapy for lung cancer. <i>Expert Opinion on Medical Diagnostics</i> , 2013, 7, 475-485.	1.6	9
239	Targeted Therapy for Non-Small Cell Lung Cancer. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 188, 907-912.	2.5	25
240	Bone Marrow Biopsy: RNA Isolation with Expression Profiling in Men with Metastatic Castration-resistant Prostate Cancer—Factors Affecting Diagnostic Success. <i>Radiology</i> , 2013, 269, 816-823.	3.6	54
241	Personalizing Therapy in Advanced Non-Small Cell Lung Cancer. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2013, 34, 822-836.	0.8	20
242	Target therapy in NSCLC patients: Relevant clinical agents and tumour molecular characterisation. <i>Molecular and Clinical Oncology</i> , 2013, 1, 575-581.	0.4	42
243	Targeted inhibition in tumors with ALK dependency. <i>Lung Cancer: Targets and Therapy</i> , 2013, 4, 1.	1.3	1
244	Membrane Phospholipids, EML4-ALK, and Hsp90 as Novel Targets in Lung Cancer Treatment. <i>Cancer Journal (Sudbury, Mass)</i> , 2013, 19, 238-246.	1.0	11
245	Response to Cabozantinib in Patients with RET Fusion-Positive Lung Adenocarcinomas. <i>Cancer Discovery</i> , 2013, 3, 630-635.	7.7	438
246	Targeted therapies of solid cancers. <i>Current Opinion in Oncology</i> , 2013, 25, 296-304.	1.1	21
247	Crizotinib-Resistant NPM-ALK Mutants Confer Differential Sensitivity to Unrelated Alk Inhibitors. <i>Molecular Cancer Research</i> , 2013, 11, 122-132.	1.5	79
248	Nonsmall Cell Lung Cancer Therapy: Insight into Multitargeted Small-Molecule Growth Factor Receptor Inhibitors. <i>BioMed Research International</i> , 2013, 2013, 1-11.	0.9	18
249	Pharmacokinetics, Clinical Indications, and Resistance Mechanisms in Molecular Targeted Therapies in Cancer. <i>Pharmacological Reviews</i> , 2013, 65, 1351-1395.	7.1	33
250	Genomic Medicine Frontier in Human Solid Tumors: Prospects and Challenges. <i>Journal of Clinical Oncology</i> , 2013, 31, 1874-1884.	0.8	101
251	The EGFR family members sustain the neoplastic phenotype of ALK+ lung adenocarcinoma via EGR1. <i>Oncogenesis</i> , 2013, 2, e43-e43.	2.1	27
252	From Bench to Bedside: Lessons Learned in Translating Preclinical Studies in Cancer Drug Development. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1441-1456.	3.0	51
253	Clinical Impact of Continued Crizotinib Administration after Isolated Central Nervous System Progression in Patients with Lung Cancer Positive for ALK Rearrangement. <i>Journal of Thoracic Oncology</i> , 2013, 8, 654-657.	0.5	82

#	ARTICLE	IF	CITATIONS
254	Experience in Integrating ALK Testing and Crizotinib into the Routine Treatment of Patients with Non-Small Cell Lung Cancer. <i>Onkologie</i> , 2013, 36, 1-1.	1.1	3
255	Immunohistochemistry is a Reliable Screening Tool for Identification of ALK Rearrangement in Non-Small-Cell Lung Carcinoma and is Antibody Dependent. <i>Journal of Thoracic Oncology</i> , 2013, 8, 45-51.	0.5	246
256	Heterogeneity of Genetic Changes Associated with Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2013, 8, 415-422.	0.5	147
258	Evaluation of safety and efficacy of tivantinib in the treatment of inoperable or recurrent non-small-cell lung cancer. <i>Cancer Management and Research</i> , 2013, 5, 15.	0.9	4
259	Clinical use of crizotinib for the treatment of non-small cell lung cancer. <i>Biologics: Targets and Therapy</i> , 2013, 7, 91.	3.0	24
260	Overview of ALK and ROS1 Rearranged Lung Cancer. <i>Tuberculosis and Respiratory Diseases</i> , 2013, 75, 236.	0.7	5
261	Inhibition of the Growth Factor MDK/Midkine by a Novel Small Molecule Compound to Treat Non-Small Cell Lung Cancer. <i>PLoS ONE</i> , 2013, 8, e71093.	1.1	50
262	Resistance to ROS1 Inhibition Mediated by EGFR Pathway Activation in Non-Small Cell Lung Cancer. <i>PLoS ONE</i> , 2013, 8, e82236.	1.1	116
263	Molecular Basis of Drug Resistance: Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Anaplastic Lymphoma Kinase Inhibitors. <i>Tuberculosis and Respiratory Diseases</i> , 2013, 75, 188.	0.7	10
264	Chronic myeloid leukemia: imatinib and next-generation ABL inhibitors. , 0, , 793-798.		1
265	Drug resistance: as complex and diverse as the disease itself. , 0, , 921-928.		0
266	Adenocarcinoma of the lung. , 2013, , 1043-1092.		1
267	Acquired Resistance to Targeted Therapies in Advanced Non-Small Cell Lung Cancer: New Strategies and New Agents. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, , e272-e278.	1.8	12
268	ALK-driven tumors and targeted therapy: focus on crizotinib. <i>Pharmacogenomics and Personalized Medicine</i> , 2014, 7, 87.	0.4	14
269	Identification of ALK Gene Alterations in Urothelial Carcinoma. <i>PLoS ONE</i> , 2014, 9, e103325.	1.1	9
270	The Human Genome Project and Personalized Medicine. , 2014, , 3418-3422.		0
271	The ALK inhibitor ASP3026 eradicates NPM-ALK+ T-cell anaplastic large-cell lymphoma <i>in vitro</i> and in a systemic xenograft lymphoma model. <i>Oncotarget</i> , 2014, 5, 5750-5763.	0.8	29
272	Resistance of Cancer Cells to Targeted Therapies Through the Activation of Compensating Signaling Loops. <i>Current Signal Transduction Therapy</i> , 2014, 8, 193-202.	0.3	57

#	ARTICLE	IF	CITATIONS
273	Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer. <i>OncoTargets and Therapy</i> , 2014, 7, 375.	1.0	22
274	Staging lung cancer: role of endobronchial ultrasound. <i>Lung Cancer: Targets and Therapy</i> , 2014, 5, 67.	1.3	3
275	New options in the management of intractable ALK(+) metastatic non-small-cell lung cancer. <i>Lung Cancer: Targets and Therapy</i> , 2014, 5, 35.	1.3	0
276	Management and Future Directions in Non-Small Cell Lung Cancer with Known Activating Mutations. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , e353-e365.	1.8	75
277	Research Highlights: Mechanisms of resistance to crizotinib in patients with <i>ALK</i> gene rearranged non-small-cell lung cancer. <i>Pharmacogenomics</i> , 2014, 15, 133-135.	0.6	9
278	Development in the diagnostic lung cancer pathway: implication for treatment. <i>Lung Cancer Management</i> , 2014, 3, 417-428.	1.5	1
279	Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 1023-1028.	1.1	219
280	Personalized Cancer Therapy. , 2014, , 671-824.		1
281	Crystal structure of EML1 reveals the basis for Hsp90 dependence of oncogenic EML4-ALK by disruption of an atypical P ² -propeller domain. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 5195-5200.	3.3	93
282	Induction of autophagy contributes to crizotinib resistance in ALK-positive lung cancer. <i>Cancer Biology and Therapy</i> , 2014, 15, 570-577.	1.5	68
283	Management of NSCLC: focus on crizotinib. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 2587-2597.	0.9	15
284	Targeting Oncogenic Drivers. <i>Progress in Tumor Research</i> , 2014, 41, 1-14.	0.1	7
285	P-loop Conformation Governed Crizotinib Resistance in G2032R-Mutated ROS1 Tyrosine Kinase: Clues from Free Energy Landscape. <i>PLoS Computational Biology</i> , 2014, 10, e1003729.	1.5	86
286	STAT3-mediated activation of microRNA cluster 17Å92 promotes proliferation and survival of ALK-positive anaplastic large cell lymphoma. <i>Haematologica</i> , 2014, 99, 116-124.	1.7	50
287	Integrating <i>In Silico</i> Prediction Methods, Molecular Docking, and Molecular Dynamics Simulation to Predict the Impact of ALK Missense Mutations in Structural Perspective. <i>BioMed Research International</i> , 2014, 2014, 1-14.	0.9	40
288	The Selective Anaplastic Lymphoma Receptor Tyrosine Kinase Inhibitor ASP3026 Induces Tumor Regression and Prolongs Survival in Non-“Small Cell Lung Cancer Model Mice. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 329-340.	1.9	58
289	Drug Resistance to Molecular Targeted Therapy and Its Consequences for Treatment Decisions in Non-Small-Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2014, 4, 190.	1.3	50
290	Developments in anaplastic large-cell lymphoma: targeting the anaplastic lymphoma kinase. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 0, , 69.	1.2	2

#	ARTICLE	IF	CITATIONS
291	Next-Generation Sequencing Reveals a Novel NSCLC ALK F1174V Mutation and Confirms ALK G1202R Mutation Confers High-Level Resistance to Alectinib (CH5424802/RO5424802) in ALK-Rearranged NSCLC Patients Who Progressed on Crizotinib. <i>Journal of Thoracic Oncology</i> , 2014, 9, 549-553.	0.5	155
292	Hypoxia induces resistance to ALK inhibitors in the H3122 non-small cell lung cancer cell line with an ALK rearrangement via epithelial-mesenchymal transition. <i>International Journal of Oncology</i> , 2014, 45, 1430-1436.	1.4	52
293	Identification of a novel HLA-A*02:01-restricted cytotoxic T lymphocyte epitope derived from the EML4-ALK fusion gene. <i>Oncology Reports</i> , 2014, 32, 33-39.	1.2	6
294	Enhanced Petri Net: elucidating the pathway-level mechanism of targeted-therapy drugs. <i>IT - Information Technology</i> , 2014, 56, 67-75.	0.6	0
295	Personalized treatment of EGFR mutant and ALK-positive patients in NSCLC. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 2693-2708.	0.9	20
296	Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease. <i>European Journal of Haematology</i> , 2014, 93, 455-468.	1.1	38
297	<i>ALK</i> Molecular Phenotype in Non-Small Cell Lung Cancer: CT Radiogenomic Characterization. <i>Radiology</i> , 2014, 272, 568-576.	3.6	140
298	<i>ALK</i> Rearrangement in a Large Series of Consecutive Non-Small Cell Lung Cancers: Comparison Between a New Immunohistochemical Approach and Fluorescence In Situ Hybridization for the Screening of Patients Eligible for Crizotinib Treatment. <i>Archives of Pathology and Laboratory Medicine</i> , 2014, 138, 1449-1458.	1.2	93
299	Molecular alterations in non-small cell lung cancer: Perspective for targeted therapy and specimen management for the bronchoscopist. <i>Respirology</i> , 2014, 19, 1117-1125.	1.3	15
300	A Personalized Treatment for Lung Cancer: Molecular Pathways, Targeted Therapies, and Genomic Characterization. <i>Advances in Experimental Medicine and Biology</i> , 2014, 799, 85-117.	0.8	98
301	Translational Pharmacokinetic-Pharmacodynamic Modeling for an Orally Available Novel Inhibitor of Anaplastic Lymphoma Kinase and c-Ros Oncogene 1. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2014, 351, 67-76.	1.3	27
302	Combined point mutation in KRAS or EGFR genes and EML4-ALK translocation in lung cancer patients. <i>Future Oncology</i> , 2014, 10, 529-532.	1.1	20
303	A Three-microRNA Signature Predicts Responses to Platinum-Based Doublet Chemotherapy in Patients with Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2014, 20, 4784-4793.	3.2	33
304	Strategies for modern biomarker and drug development in oncology. <i>Journal of Hematology and Oncology</i> , 2014, 7, 70.	6.9	98
305	Identification and Characterization of ALK Kinase Splicing Isoforms in Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2014, 9, 248-253.	0.5	15
306	Large-Scale Screening and Molecular Characterization of EML4-ALK Fusion Variants in Archival Non-Small-Cell Lung Cancer Tumor Specimens Using Quantitative Reverse Transcription Polymerase Chain Reaction Assays. <i>Journal of Thoracic Oncology</i> , 2014, 9, 18-25.	0.5	58
307	Implementing precision medicine initiatives in the clinic. <i>Current Opinion in Oncology</i> , 2014, 26, 340-346.	1.1	17
308	ALK inhibitors and advanced non-small cell lung cancer (Review). <i>International Journal of Oncology</i> , 2014, 45, 499-508.	1.4	37

#	ARTICLE	IF	CITATIONS
309	A New Human Lung Adenocarcinoma Cell Line Harboring the EML4-ALK Fusion Gene. Japanese Journal of Clinical Oncology, 2014, 44, 963-968.	0.6	11
310	Moving from histological subtyping to molecular characterization: new treatment opportunities in advanced non-small-cell lung cancer. Expert Review of Anticancer Therapy, 2014, 14, 1495-1513.	1.1	8
311	Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors. Clinical Epidemiology, 2014, 6, 423.	1.5	139
312	A Systemic Review of Resistance Mechanisms and Ongoing Clinical Trials in ALK-Rearranged Non-Small Cell Lung Cancer. Frontiers in Oncology, 2014, 4, 174.	1.3	22
313	Polimorfismos genticos e carcinoma de pulmo de clulas no pequenas: os paradigmas do futuro. Einstein (Sao Paulo, Brazil), 2014, 12, 524-526.	0.3	4
314	<i>paclitaxel for the management of patients with advanced non-small-cell lung cancer. Expert Review of Anticancer Therapy, 2014, 14, 129-141.	1.1	14
315	Secondary Mutations at I1171 in the ALK Gene Confer Resistance to Both Crizotinib and Alectinib. Journal of Thoracic Oncology, 2014, 9, e86-e87.	0.5	69
316	Cancer evolution: the final frontier of precision medicine?. Annals of Oncology, 2014, 25, 549-551.	0.6	31
317	The kinase ALK stimulates the kinase ERK5 to promote the expression of the oncogene MYCN in neuroblastoma. Science Signaling, 2014, 7, ra102.	1.6	80
318	Biomarkers in Oncology and Nephrology. , 2014, , 21-38.		5
319	Targeted Therapies in Non-Small Cell Lung Cancer: Emerging Oncogene Targets Following the Success of Epidermal Growth Factor Receptor. Seminars in Oncology, 2014, 41, 110-125.	0.8	60
320	ALK inhibitors of bis-ortho-alkoxy-para-piperazinesubstituted-pyrimidines and -triazines for cancer treatment. Archives of Pharmacal Research, 2014, 37, 1130-1138.	2.7	11
322	Targeting ALK in patients with advanced Non Small Cell Lung Cancer: Biology, diagnostic and therapeutic options. Critical Reviews in Oncology/Hematology, 2014, 89, 358-365.	2.0	27
323	Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma. Journal of Cancer Research and Clinical Oncology, 2014, 140, 589-598.	1.2	30
324	Maintaining Low BCR-ABL Signaling Output to Restrict CML Progression and Enable Persistence. Current Hematologic Malignancy Reports, 2014, 9, 9-16.	1.2	9
325	Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer. Lung Cancer, 2014, 83, 37-43.	0.9	86
326	Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to Crizotinib. Journal of Medicinal Chemistry, 2014, 57, 1170-1187.	2.9	100
327	Crizotinib. Recent Results in Cancer Research, 2014, 201, 197-205.	1.8	22

#	ARTICLE	IF	CITATIONS
328	Systems Analysis of Human Multigene Disorders. <i>Advances in Experimental Medicine and Biology</i> , 2014, 799, v - viii.	0.8	4
329	Molecular Testing in Cancer. , 2014, , .		2
330	3D-QSAR and molecular fragment replacement study on diaminopyrimidine and pyrrolotriazine ALK inhibitors. <i>Journal of Molecular Structure</i> , 2014, 1067, 127-137.	1.8	13
331	Small Molecules in Oncology. <i>Recent Results in Cancer Research</i> , 2014, , .	1.8	4
332	ALK-€positive non-€small cell lung cancer: Mechanisms of resistance and emerging treatment options. <i>Cancer</i> , 2014, 120, 2392-2402.	2.0	50
333	Implications of intratumour heterogeneity for treatment stratification. <i>Journal of Pathology</i> , 2014, 232, 264-273.	2.1	53
334	The genetic complexity of common cancers and the promise of personalized medicine: is there any hope?. <i>Journal of Pathology</i> , 2014, 232, 274-282.	2.1	48
335	The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-€Small Cell Lung Cancer. <i>Cancer Discovery</i> , 2014, 4, 662-673.	7.7	720
336	Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. <i>Annals of Oncology</i> , 2014, 25, 415-422.	0.6	204
337	ALK Mutations Confer Differential Oncogenic Activation and Sensitivity to ALK Inhibition Therapy in Neuroblastoma. <i>Cancer Cell</i> , 2014, 26, 682-694.	7.7	302
338	Aspects biologiques des cancers bronchiques. <i>Revue Des Maladies Respiratoires Actualites</i> , 2014, 6, 311-319.	0.0	0
339	Anaplastic lymphoma kinase rearrangement in lung Cancer: Its biological and clinical significance. <i>Respiratory Investigation</i> , 2014, 52, 330-338.	0.9	18
340	Concise Review: Cancer Cells Escape from Oncogene Addiction: Understanding the Mechanisms Behind Treatment Failure for More Effective Targeting. <i>Stem Cells</i> , 2014, 32, 1373-1379.	1.4	27
341	Acquired Resistance to Dasatinib in Lung Cancer Cell Lines Conferred by<i>DDR2</i>Gatekeeper Mutation and<i>NF1</i>Loss. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 475-482.	1.9	51
342	The Fibroblast Growth Factor Receptor Genetic Status as a Potential Predictor of the Sensitivity to CH5183284/Debio 1347, a Novel Selective FGFR Inhibitor. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 2547-2558.	1.9	106
343	Anaplastic lymphoma kinase (ALK) inhibitors: a review of design and discovery. <i>MedChemComm</i> , 2014, 5, 1266-1279.	3.5	21
344	Molecular analysis of cell-free circulating DNA for the diagnosis of somatic mutations associated with resistance to tyrosine kinase inhibitors in non-small-cell lung cancer. <i>Expert Review of Molecular Diagnostics</i> , 2014, 14, 453-468.	1.5	17
345	Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib. <i>Clinical Cancer Research</i> , 2014, 20, 5686-5696.	3.2	261

#	ARTICLE	IF	CITATIONS
346	Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. <i>Lancet Oncology</i> , 2014, 15, 1119-1128.	5.1	631
347	Novel Anaplastic Lymphoma Kinase Inhibitors Targeting Clinically Acquired Resistance. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 1167-1169.	2.9	6
348	Translating Genomics for Precision Cancer Medicine. <i>Annual Review of Genomics and Human Genetics</i> , 2014, 15, 395-415.	2.5	63
349	Somatic alterations as the basis for resistance to targeted therapies. <i>Journal of Pathology</i> , 2014, 232, 244-254.	2.1	31
351	Differential knockdown of TGF- β ligands in a three-dimensional co-culture tumor-stromal interaction model of lung cancer. <i>BMC Cancer</i> , 2014, 14, 580.	1.1	20
352	Clinical challenges in targeting anaplastic lymphoma kinase in advanced non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 437-446.	1.1	29
353	Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer. <i>Journal of Molecular Medicine</i> , 2014, 92, 697-707.	1.7	58
354	Tumour heterogeneity and the evolution of polyclonal drug resistance. <i>Molecular Oncology</i> , 2014, 8, 1095-1111.	2.1	347
355	Novel 2,4-dianilino-5-fluoropyrimidine derivatives possessing ALK inhibitory activities. <i>Archives of Pharmacal Research</i> , 2014, 37, 873-881.	2.7	9
356	Modern Cancer Drug Discovery. , 2014, , 3-53.		8
357	Acquired resistance to TKIs in solid tumours: learning from lung cancer. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 473-481.	12.5	740
358	Current concepts on the molecular pathology of non-small cell lung carcinoma. <i>Seminars in Diagnostic Pathology</i> , 2014, 31, 306-313.	1.0	43
360	Second-Generation ALK Inhibitors: Filling the Non α -MET β -Gap. <i>Cancer Discovery</i> , 2014, 4, 634-636.	7.7	8
361	Overcoming the resistance to Crizotinib in patients with Non-Small Cell Lung Cancer harboring EML4/ALK translocation. <i>Lung Cancer</i> , 2014, 84, 110-115.	0.9	41
362	ALK inhibitors in the treatment of advanced NSCLC. <i>Cancer Treatment Reviews</i> , 2014, 40, 300-306.	3.4	152
363	Ceritinib for treatment of ALK-rearranged advanced non-small-cell lung cancer. <i>Future Oncology</i> , 2014, 10, 1925-1939.	1.1	10
364	Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance. <i>Cancer Letters</i> , 2014, 351, 215-221.	3.2	190
365	Drug resistance to targeted therapies: DÃ©jà vu all over again. <i>Molecular Oncology</i> , 2014, 8, 1067-1083.	2.1	187

#	ARTICLE	IF	CITATIONS
366	ALK Inhibitors: What Is the Best Way to Treat Patients With ALK+ Non-Small-Cell Lung Cancer?. <i>Clinical Lung Cancer</i> , 2014, 15, 313-319.	1.1	26
367	Reading between the lines; understanding drug response in the post genomic era. <i>Molecular Oncology</i> , 2014, 8, 1112-1119.	2.1	12
368	Review of the current targeted therapies for non-small-cell lung cancer. <i>World Journal of Clinical Oncology</i> , 2014, 5, 576.	0.9	59
369	Crizotinib Can Overcome Acquired Resistance to CH5424802: Is Amplification of the MET Gene a Key Factor?. <i>Journal of Thoracic Oncology</i> , 2014, 9, e27-e28.	0.5	85
370	Marked tumor response to crizotinib after 4 years of maintenance pemetrexed in a patient with anaplastic lymphoma kinase-positive non-small-cell lung cancer. <i>Molecular and Clinical Oncology</i> , 2014, 2, 567-570.	0.4	2
373	Approaches for measuring signalling plasticity in the context of resistance to targeted cancer therapies. <i>Biochemical Society Transactions</i> , 2014, 42, 791-797.	1.6	5
374	Combination of BIBW2992 and ARQ 197 is effective against erlotinib-resistant human lung cancer cells with the EGFR T790M mutation. <i>Oncology Reports</i> , 2014, 32, 341-347.	1.2	7
375	Nestin regulates proliferation, migration, invasion and stemness of lung adenocarcinoma. <i>International Journal of Oncology</i> , 2014, 44, 1118-1130.	1.4	69
376	Zielgerichtetes Vorgehen gegen onkogene Faktoren. <i>Karger Kompass Onkologie</i> , 2015, 2, 61-70.	0.0	0
377	Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK. <i>Cancer Medicine</i> , 2015, 4, 953-965.	1.3	72
378	Implementation of modern therapy approaches and research for non-small cell lung cancer in Japan. <i>Respirology</i> , 2015, 20, 199-208.	1.3	4
379	The EML4-ALK oncogene: targeting an essential growth driver in human cancer. <i>Proceedings of the Japan Academy Series B: Physical and Biological Sciences</i> , 2015, 91, 193-201.	1.6	21
381	Targeted therapies in CLL: mechanisms of resistance and strategies for management. <i>Blood</i> , 2015, 126, 471-477.	0.6	112
383	The Role of the Anaplastic Lymphoma Kinase Receptor in Neuroblastoma. <i>Pediatric and Adolescent Medicine</i> , 0, , 107-120.	0.4	0
384	Association between EML4-ALK fusion gene and thymidylate synthase mRNA expression in non-small cell lung cancer tissues. <i>Experimental and Therapeutic Medicine</i> , 2015, 9, 2151-2154.	0.8	12
385	Design, Synthesis, and Evaluation of 2,4-Di(piperidine-substituted-anilino)pyrimidine Derivatives as ALK Inhibitors. <i>Bulletin of the Korean Chemical Society</i> , 2015, 36, 1929-1932.	1.0	1
386	Design, Synthesis, and Evaluation of 2-Anilino-4-(3,5-dicarboxamidospiperidine)-pyrimidines as Anaplastic Lymphoma Kinase Inhibitors. <i>Bulletin of the Korean Chemical Society</i> , 2015, 36, 2397-2400.	1.0	0
387	Landscape of gene fusions in epithelial cancers: seq and ye shall find. <i>Genome Medicine</i> , 2015, 7, 129.	3.6	127

#	ARTICLE	IF	CITATIONS
388	Targeted therapy: resistance and re-sensitization. Chinese Journal of Cancer, 2015, 34, 496-501.	4.9	21
390	Companion Diagnostics and Molecular Imaging. Cancer Journal (Sudbury, Mass), 2015, 21, 213-217.	1.0	15
391	Anaplastic Lymphoma Kinase as a Therapeutic Target in Non-Small Cell Lung Cancer. Cancer Journal (Sudbury, Mass), 2015, 21, 378-382.	1.0	20
392	Evaluation of azacitidine and entinostat as sensitization agents to cytotoxic chemotherapy in preclinical models of non-small cell lung cancer. Oncotarget, 2015, 6, 56-70.	0.8	27
393	Profile of ceritinib in the treatment of ALK+ metastatic non-small-cell lung cancer. Lung Cancer: Targets and Therapy, 2015, 6, 35.	1.3	2
394	The Pharmaceutical Applications of Next Generation Sequencing in Oncology Drug Designing and Development. Journal of Next Generation Sequencing & Applications, 2015, 02, .	0.3	1
395	Genetics of Bladder Malignant Tumors in Childhood. Current Genomics, 2015, 17, 14-32.	0.7	14
396	The distinctive nature of adenocarcinoma of the lung. OncoTargets and Therapy, 2015, 8, 2399.	1.0	16
397	Clinical Challenges to Current Molecularly Targeted Therapies in Lung Cancer. Archives in Cancer Research, 2015, 3, .	0.3	1
398	The anaplastic lymphoma kinase as an oncogene in solid tumors. Frontiers in Bioscience - Scholar, 2015, 7, 269-282.	0.8	5
399	Imaging Characteristics in ALK-Fusion-Positive Lung Adenocarcinomas by Using HRCT. Annals of Thoracic and Cardiovascular Surgery, 2015, 21, 102-108.	0.3	20
400	Personalized treatment options for ALK-positive metastatic non-small-cell lung cancer: potential role for Ceritinib. Pharmacogenomics and Personalized Medicine, 2015, 8, 145.	0.4	15
401	Combating Acquired Resistance to Tyrosine Kinase Inhibitors in Lung Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e165-e173.	1.8	16
402	Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer. Cancers, 2015, 7, 763-783.	1.7	59
403	Crizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancer. Drug Design, Development and Therapy, 2015, 9, 5491.	2.0	1
404	Novel targeted therapies for resistant ALK-rearranged non-small-cell lung cancer: ceritinib and beyond. OncoTargets and Therapy, 2015, 8, 885.	1.0	12
405	ALK Kinase Domain Mutations in Primary Anaplastic Large Cell Lymphoma: Consequences on NPM-ALK Activity and Sensitivity to Tyrosine Kinase Inhibitors. PLoS ONE, 2015, 10, e0121378.	1.1	7
406	Identification of Reprogrammed Myeloid Cell Transcriptomes in NSCLC. PLoS ONE, 2015, 10, e0129123.	1.1	17

#	ARTICLE	IF	CITATIONS
407	Computational drug ZINPIP-Analog an ultimate solution to cure conserved domains of mutant EGFR, ALK and BRAF Proteins in NSCLC. International Current Pharmaceutical Journal, 2015, 4, 396-401.	0.2	1
408	Analysis of ERBB Ligand-Induced Resistance Mechanism to Crizotinib by Primary Culture of Lung Adenocarcinoma with EML4-ALK Fusion Gene. Journal of Thoracic Oncology, 2015, 10, 527-530.	0.5	32
409	Therapeutically Targetable ALK Mutations in Leukemia. Cancer Research, 2015, 75, 2146-2150.	0.4	20
410	Treatment, overall survival, and costs in patients with <i>ALK</i> -positive non-small-cell lung cancer after crizotinib monotherapy. Current Medical Research and Opinion, 2015, 31, 1587-1597.	0.9	23
411	Cabozantinib Overcomes Crizotinib Resistance in ROS1 Fusion-Positive Cancer. Clinical Cancer Research, 2015, 21, 166-174.	3.2	172
412	Personalized Therapy of Cancer. , 2015, , 199-381.		1
413	Targeting EGFR in lung cancer: Lessons learned and future perspectives. Molecular Aspects of Medicine, 2015, 45, 67-73.	2.7	42
414	Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397. Cancer Discovery, 2015, 5, 668-679.	7.7	145
416	Intracellular signals of lung cancer cells as possible therapeutic targets. Cancer Science, 2015, 106, 489-496.	1.7	12
417	Testing for oncogenic molecular aberrations in cell-free DNA-based liquid biopsies in the clinic: are we there yet?. Expert Review of Molecular Diagnostics, 2015, 15, 1631-1644.	1.5	53
418	Anaplastic lymphoma kinase: Role in cancer and therapy perspective. Cancer Biology and Therapy, 2015, 16, 1691-1701.	1.5	32
419	Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer. American Journal of Health-System Pharmacy, 2015, 72, 1456-1462.	0.5	20
420	First line crizotinib in anaplastic lymphoma kinase (ALK) rearranged squamous cell lung cancer. Lung Cancer, 2015, 90, 614-616.	0.9	16
421	Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation. Journal of Medicinal Chemistry, 2015, 58, 9296-9308.	2.9	34
423	Phase I Study of Ceritinib (LDK378) in Japanese Patients with Advanced, Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer or Other Tumors. Journal of Thoracic Oncology, 2015, 10, 1058-1066.	0.5	66
424	Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer. International Journal of Oncology, 2015, 46, 1025-1030.	1.4	42
425	Advances in Molecular Biology of Lung Disease. Chest, 2015, 148, 1063-1072.	0.4	18
426	Updated Evidence on the Mechanisms of Resistance to ALK Inhibitors and Strategies to Overcome Such Resistance: Clinical and Preclinical Data. Oncology Research and Treatment, 2015, 38, 291-298.	0.8	82

#	ARTICLE	IF	CITATIONS
427	Future options for ALK-positive non-small cell lung cancer. <i>Lung Cancer</i> , 2015, 87, 211-219.	0.9	50
428	Intérêt de l'immunohistochimie à visée pronostique dans les carcinomes bronchiques non à petites cellules : applications et limites actuelles. <i>Revue Francophone Des Laboratoires</i> , 2015, 2015, 37-47.	0.0	0
429	<i>In vivo</i> imaging models of bone and brain metastases and pleural carcinomatosis with a novel human EML4-ALK lung cancer cell line. <i>Cancer Science</i> , 2015, 106, 244-252.	1.7	32
430	Alectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistance. <i>Acta Pharmaceutica Sinica B</i> , 2015, 5, 34-37.	5.7	67
431	The Effect of Mutations on Drug Sensitivity and Kinase Activity of Fibroblast Growth Factor Receptors: A Combined Experimental and Theoretical Study. <i>EBioMedicine</i> , 2015, 2, 194-204.	2.7	60
432	Importance of protein flexibility in ranking inhibitor affinities: modeling the binding mechanisms of piperidine carboxamides as Type 11/2 ALK inhibitors. <i>Physical Chemistry Chemical Physics</i> , 2015, 17, 6098-6113.	1.3	48
433	Computational Investigation and Experimental Validation of Crizotinib Resistance Conferred by C1156Y Mutant Anaplastic Lymphoma Kinase. <i>Molecular Informatics</i> , 2015, 34, 105-114.	1.4	11
434	The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer. <i>Cancer</i> , 2015, 121, E1-6.	2.0	55
435	Systemic treatment of advanced hepatocellular carcinoma: From disillusion to new horizons. <i>European Journal of Cancer</i> , 2015, 51, 327-339.	1.3	63
436	Molecular histology of lung cancer: From targets to treatments. <i>Cancer Treatment Reviews</i> , 2015, 41, 361-375.	3.4	142
437	Transcriptome Analysis of Individual Stromal Cell Populations Identifies Stroma-Tumor Crosstalk in Mouse Lung Cancer Model. <i>Cell Reports</i> , 2015, 10, 1187-1201.	2.9	137
438	Rebiopsy during disease progression in patients treated by TKI for oncogene-addicted NSCLC. <i>Targeted Oncology</i> , 2015, 10, 247-253.	1.7	54
439	Pharmacogenomics and targeted therapy of cancer: Focusing on non-small cell lung cancer. <i>European Journal of Pharmacology</i> , 2015, 754, 82-91.	1.7	31
440	Crizotinib resistance in acute myeloid leukemia with inv(2)(p23q13)/RAN binding protein 2 (RANBP2) anaplastic lymphoma kinase (ALK) fusion and monosomy 7. <i>Cancer Genetics</i> , 2015, 208, 85-90.	0.2	13
441	Inflammation and Lung Cancer. , 2015, , .		2
442	Biomarkers and targeted systemic therapies in advanced non-small cell lung cancer. <i>Molecular Aspects of Medicine</i> , 2015, 45, 55-66.	2.7	26
443	Inflammation and Lung Cancer: The Link to Angiogenesis. , 2015, , 137-159.		0
444	Similitude and evolution of treatment algorithms. <i>Current Medical Research and Opinion</i> , 2015, 31, 1583-1585.	0.9	0

#	ARTICLE	IF	CITATIONS
445	Precision medicine for metastatic breast cancer—limitations and solutions. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 693-704.	12.5	272
446	A historical overview of protein kinases and their targeted small molecule inhibitors. <i>Pharmacological Research</i> , 2015, 100, 1-23.	3.1	391
447	Tackling Crizotinib Resistance: The Pathway from Drug Discovery to the Pediatric Clinic. <i>Cancer Research</i> , 2015, 75, 2770-2774.	0.4	26
448	Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: Recent Progress and Future Directions. <i>Drugs</i> , 2015, 75, 1059-1070.	4.9	17
449	PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models. <i>Cancer Cell</i> , 2015, 28, 70-81.	7.7	389
450	EML4-ALK induces epithelial—mesenchymal transition consistent with cancer stem cell properties in H1299 non-small cell lung cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2015, 459, 398-404.	1.0	28
451	Hypermethylation of the CpG dinucleotide in epidermal growth factor receptor codon 790: implications for a mutational hotspot leading to the T790M mutation in non—small-cell lung cancer. <i>Cancer Genetics</i> , 2015, 208, 271-278.	0.2	12
453	An interaction map of small-molecule kinase inhibitors with anaplastic lymphoma kinase (ALK) mutants in ALK-positive non-small cell lung cancer. <i>Biochimie</i> , 2015, 112, 111-120.	1.3	22
454	Clinical management of breast cancer heterogeneity. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 381-394.	12.5	400
455	Targeting oncogenic drivers in lung cancer: celebrating a decade of progress. <i>Memo - Magazine of European Medical Oncology</i> , 2015, 8, 81-83.	0.3	1
456	Novel ALK inhibitors in clinical use and development. <i>Journal of Hematology and Oncology</i> , 2015, 8, 17.	6.9	81
457	Peptides derived from the dependence receptor ALK are proapoptotic for ALK-positive tumors. <i>Cell Death and Disease</i> , 2015, 6, e1736-e1736.	2.7	5
458	A new generation of cancer genome diagnostics for routine clinical use: overcoming the roadblocks to personalized cancer medicine. <i>Annals of Oncology</i> , 2015, 26, 1830-1837.	0.6	43
459	Alectinib: a selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer. <i>Expert Review of Respiratory Medicine</i> , 2015, 9, 255-268.	1.0	24
460	Textbook of Personalized Medicine. , 2015, , .		27
461	Therapeutic management of ALK+nonsmall cell lung cancer patients. <i>European Respiratory Journal</i> , 2015, 46, 230-242.	3.1	21
462	A Functional Landscape of Resistance to ALK Inhibition in Lung Cancer. <i>Cancer Cell</i> , 2015, 27, 397-408.	7.7	150
463	Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK—Positive Anaplastic Large Cell Lymphoma. <i>Molecular Cancer Research</i> , 2015, 13, 775-783.	1.5	52

#	ARTICLE	IF	CITATIONS
464	The efficacy of crizotinib in patients with <i>ALK</i>-positive nonsmall cell lung cancer. Therapeutic Advances in Respiratory Disease, 2015, 9, 97-104.	1.0	4
465	MET/HGF targeted drugs as potential therapeutic strategies in non-small cell lung cancer. Pharmacological Research, 2015, 102, 90-106.	3.1	4
466	Targeting brain metastases in ALK-rearranged non-small-cell lung cancer. Lancet Oncology, The, 2015, 16, e510-e521.	5.1	160
467	Overcoming resistance to targeted therapies in NSCLC: current approaches and clinical application. Therapeutic Advances in Medical Oncology, 2015, 7, 263-273.	1.4	47
468	Overcoming Resistance to Targeted Therapies in Cancer. Seminars in Oncology, 2015, 42, 896-908.	0.8	36
469	c-Myc Alterations Confer Therapeutic Response and Acquired Resistance to c-Met Inhibitors in MET-Addicted Cancers. Cancer Research, 2015, 75, 4548-4559.	0.4	47
470	CRISPR/Cas9: molecular tool for gene therapy to target genome and epigenome in the treatment of lung cancer. Cancer Gene Therapy, 2015, 22, 509-517.	2.2	42
471	The ALK Receptor Family. , 2015, , 1-51.		0
472	Agents in the preclinical development stage for non-small cell lung cancer. Expert Review of Anticancer Therapy, 2015, 15, 1361-1366.	1.1	0
473	P-glycoprotein confers acquired resistance to 17-DMAG in lung cancers with an ALK rearrangement. BMC Cancer, 2015, 15, 553.	1.1	16
474	Novel tetracyclic benzo[b]carbazolones as highly potent and orally bioavailable ALK inhibitors: Design, synthesis, and structure-activity relationship study. European Journal of Medicinal Chemistry, 2015, 105, 39-56.	2.6	13
475	An Efficient Synthesis of Ceritinib (LDK378) Using a Sandmeyer Reaction. Journal of Chemical Research, 2015, 39, 475-477.	0.6	1
476	Efficacy of a Cancer Vaccine against <i>ALK</i>-Rearranged Lung Tumors. Cancer Immunology Research, 2015, 3, 1333-1343.	1.6	42
477	Cancer Genetics and Implications for Clinical Management. Surgical Clinics of North America, 2015, 95, 919-934.	0.5	6
478	Lung cancer: Biology and treatment options. Biochimica Et Biophysica Acta: Reviews on Cancer, 2015, 1856, 189-210.	3.3	526
479	Lung and Mediastinal Tumors. , 2015, , 221-268.		0
480	Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E5381-90.	3.3	93
481	New Treatment Options for ALK-Rearranged Non-Small Cell Lung Cancer. Current Treatment Options in Oncology, 2015, 16, 49.	1.3	28

#	ARTICLE	IF	CITATIONS
482	Treating patients with <i>ALK</i> -positive non-small cell lung cancer: latest evidence and management strategy. <i>Therapeutic Advances in Medical Oncology</i> , 2015, 7, 274-290.	1.4	20
483	Crizotinib: an orphan drug for treating non-small-cell lung cancer. <i>Expert Opinion on Orphan Drugs</i> , 2015, 3, 1209-1218.	0.5	1
484	Interstitial lung disease induced by alectinib (CH5424802/RO5424802). <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 221-224.	0.6	16
485	Discovery of Novel 2,4-Diarylaminopyrimidine Analogues (DAAPalogues) Showing Potent Inhibitory Activities against Both Wild-type and Mutant ALK Kinases. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 197-211.	2.9	43
486	Mechanistic Understanding of Translational Pharmacokinetic-Pharmacodynamic Relationships in Nonclinical Tumor Models: A Case Study of Orally Available Novel Inhibitors of Anaplastic Lymphoma Kinase. <i>Drug Metabolism and Disposition</i> , 2015, 43, 54-62.	1.7	21
489	Genomic Applications in Pathology. , 2015, , .		1
490	Translational Medicine Case Studies and Reports. , 2016, , 135-156.		0
491	The steady progress of targeted therapies, promising advances for lung cancer. <i>E-cancermedicalscience</i> , 2016, 10, 638.	0.6	6
492	New treatment options for ALK+ advanced non-small-cell lung cancer: critical appraisal of ceritinib. <i>Therapeutics and Clinical Risk Management</i> , 2016, 12, 735.	0.9	13
493	A patient previously treated with ALK inhibitors for central nervous system lesions from ALK rearranged lung cancer: a case report. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 6059-6063.	1.0	4
494	Identification of a novel inherited ALK variant M1199L in the WNT type of medulloblastoma. <i>Folia Neuropathologica</i> , 2016, 1, 23-30.	0.5	9
495	Targeted Therapy in Brain Metastases: Ready for Primetime?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e123-e130.	1.8	35
496	Efficacy of crizotinib in ALK fusion variants. <i>Journal of Thoracic Disease</i> , 2016, 8, E1381-E1383.	0.6	8
497	Tackling ALK in non-small cell lung cancer: the role of novel inhibitors. <i>Translational Lung Cancer Research</i> , 2016, 5, 301-321.	1.3	37
498	Second-generation anaplastic lymphoma kinase inhibitors: revolutionary or evolutionary?. <i>Journal of Thoracic Disease</i> , 2016, 8, 1425-1427.	0.6	0
499	Editorial on the article entitled "Crizotinib efficacy and safety in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer in a phase I/II trial". <i>Journal of Thoracic Disease</i> , 2016, 8, E1287-E1292.	0.6	2
500	Current evidence in support of the second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor alectinib for the treatment of non-small cell lung cancer positive for ALK translocation. <i>Journal of Thoracic Disease</i> , 2016, 8, E1311-E1316.	0.6	2
501	ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance. <i>Oncotarget</i> , 2016, 7, 12289-12304.	0.8	22

#	ARTICLE	IF	CITATIONS
502	Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications. <i>Disease Markers</i> , 2016, 2016, 1-14.	0.6	13
503	Non-Invasive Methods to Monitor Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer: <i>Where Do We Stand?</i> . <i>International Journal of Molecular Sciences</i> , 2016, 17, 1186.	1.8	20
504	Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 6361-6376.	1.0	21
505	Focus on Alectinib and Competitor Compounds for Second-Line Therapy in ALK-Rearranged NSCLC. <i>Frontiers in Medicine</i> , 2016, 3, 65.	1.2	8
506	Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC. <i>Frontiers in Oncology</i> , 2016, 6, 112.	1.3	23
507	Discordance of Mutation Statuses of Epidermal Growth Factor Receptor and K-ras between Primary Adenocarcinoma of Lung and Brain Metastasis. <i>International Journal of Molecular Sciences</i> , 2016, 17, 524.	1.8	28
508	Patients harboring EGFR mutation after primary resistance to crizotinib and response to EGFR-tyrosine kinase inhibitor. <i>OncoTargets and Therapy</i> , 2016, 9, 211.	1.0	7
509	ALK inhibitors for clinical use in cancer therapy. <i>Frontiers in Bioscience - Elite</i> , 2016, 8, 46-60.	0.9	3
510	Crizotinib-Resistant <i>ROS1</i> Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for <i>ROS1</i> - and <i>ALK</i> -Rearranged Lung Cancers. <i>Clinical Cancer Research</i> , 2016, 22, 5983-5991.	3.2	124
511	Malignant pleural effusion cell blocks are substitutes for tissue in <i>EML4-ALK</i> rearrangement detection in patients with advanced non-small cell lung cancer. <i>Cytopathology</i> , 2016, 27, 433-443.	0.4	12
512	Efficacy of crizotinib in first-line treatment of adults with ALK-positive advanced NSCLC. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1693-1701.	0.9	16
513	The pharmacogenomics of drug resistance to protein kinase inhibitors. <i>Drug Resistance Updates</i> , 2016, 28, 28-42.	6.5	24
514	The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer. <i>Cancer and Metastasis Reviews</i> , 2016, 35, 575-588.	2.7	237
515	Post-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancer. <i>BMC Cancer</i> , 2016, 16, 568.	1.1	1
516	Re-Evaluating Progression in an Era of Progress: A Review of First- and Second-Line Treatment Options in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2016, 21, 755-761.	1.9	21
517	A convex optimization approach to cancer treatment to address tumor heterogeneity and imperfect drug penetration in physiological compartments. , 2016, , .		11
518	The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN. <i>DMM Disease Models and Mechanisms</i> , 2016, 9, 941-52.	1.2	62
519	Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials. <i>Oncologist</i> , 2016, 21, 684-691.	1.9	85

#	ARTICLE	IF	CITATIONS
520	Molecular characterization of pulmonary sarcomatoid carcinoma: analysis of 33 cases. <i>Modern Pathology</i> , 2016, 29, 824-831.	2.9	68
521	Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib. <i>Clinical Lung Cancer</i> , 2016, 17, 528-534.	1.1	39
522	Deciphering intra-tumor heterogeneity of lung adenocarcinoma confirms that dominant, branching, and private gene mutations occur within individual tumor nodules. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 468, 651-662.	1.4	14
523	Discovery of Low Micromolar Dual Inhibitors for Wild Type and L1196M Mutant of Anaplastic Lymphoma Kinase through Structure-Based Virtual Screening. <i>Journal of Chemical Information and Modeling</i> , 2016, 56, 802-810.	2.5	9
524	Discovery of potential ALK inhibitors by virtual screening approach. <i>3 Biotech</i> , 2016, 6, 21.	1.1	5
525	Emerging treatment for ALK-positive lung cancer. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 147-155.	1.0	4
526	Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non-Small-Cell Lung Cancer: Analysis and Literature Review. <i>Clinical Lung Cancer</i> , 2016, 17, e77-e94.	1.1	27
527	Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 737-749.	1.5	24
528	Clinical Implications of Genomic Discoveries in Lung Cancer. <i>New England Journal of Medicine</i> , 2016, 374, 1864-1873.	13.9	235
529	The role of the ALK receptor in cancer biology. <i>Annals of Oncology</i> , 2016, 27, iii4-iii15.	0.6	250
530	Insight into drug resistance mechanisms and discovery of potential inhibitors against wild-type and L1196M mutant ALK from FDA-approved drugs. <i>Journal of Molecular Modeling</i> , 2016, 22, 231.	0.8	10
531	Resisting Resistance: Targeted Therapies in Lung Cancer. <i>Trends in Cancer</i> , 2016, 2, 350-364.	3.8	162
532	Emergence of resistance to tyrosine kinase inhibitors in non-small-cell lung cancer can be delayed by an upfront combination with the HSP90 inhibitor onalespib. <i>British Journal of Cancer</i> , 2016, 115, 1069-1077.	2.9	26
533	Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 2253-2266.	0.9	26
534	Acquired MET D1228V Mutation and Resistance to MET Inhibition in Lung Cancer. <i>Cancer Discovery</i> , 2016, 6, 1334-1341.	7.7	133
535	Metastatic Lung Cancer: Emerging Therapeutic Strategies. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2016, 37, 736-749.	0.8	1
536	Predictive and Prognostic Biomarkers in Non-Small Cell Lung Cancer. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2016, 37, 760-770.	0.8	50
537	Design, synthesis and biological evaluation of novel 4-arylamino-pyrimidine derivatives possessing a hydrazone moiety as dual inhibitors of L1196M ALK and ROS1. <i>European Journal of Medicinal Chemistry</i> , 2016, 123, 80-89.	2.6	23

#	ARTICLE	IF	CITATIONS
538	Metabolism in Cancer. Recent Results in Cancer Research, 2016, , .	1.8	5
539	Metabolic Features of Cancer Treatment Resistance. Recent Results in Cancer Research, 2016, 207, 135-156.	1.8	34
540	Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease. Lancet, The, 2016, 388, 1002-1011.	6.3	132
541	Discovery of Clinical Candidate CEP-37440, a Selective Inhibitor of Focal Adhesion Kinase (FAK) and Anaplastic Lymphoma Kinase (ALK). Journal of Medicinal Chemistry, 2016, 59, 7478-7496.	2.9	69
542	Diagnosis and Molecular Classification of Lung Cancer. Cancer Treatment and Research, 2016, 170, 25-46.	0.2	172
543	Resistance to Therapy. Cancer Treatment and Research, 2016, 170, 183-202.	0.2	10
544	Protocol Design for the Bench to Bed Trial in Alectinib-Refractory Non-“Small-Cell Lung Cancer Patients Harboring the EML4-ALK Fusion Gene (ALRIGHT/OLCSG1405). Clinical Lung Cancer, 2016, 17, 602-605.	1.1	10
545	The rise of genomic profiling in ovarian cancer. Expert Review of Molecular Diagnostics, 2016, 16, 1337-1351.	1.5	18
546	Coupling an EML4-ALK-centric interactome with RNA interference identifies sensitizers to ALK inhibitors. Science Signaling, 2016, 9, rs12.	1.6	27
547	The role of alectinib in the treatment of advanced ALK-rearranged non-small-cell lung cancer. Expert Review of Anticancer Therapy, 2016, 16, 1227-1233.	1.1	6
548	Crizotinib resistance: implications for therapeutic strategies. Annals of Oncology, 2016, 27, iii42-iii50.	0.6	109
549	The use of cellular thermal shift assay (CETSA) to study Crizotinib resistance in ALK-expressing human cancers. Scientific Reports, 2016, 6, 33710.	1.6	35
550	Metabolism-based structure optimization: Discovery of a potent and orally available tyrosine kinase ALK inhibitor bearing the tetracyclic benzo[b]carbazolone core. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 5399-5402.	1.0	5
551	Discovering and understanding oncogenic gene fusions through data intensive computational approaches. Nucleic Acids Research, 2016, 44, 4487-4503.	6.5	133
552	Targeting EGFR and ALK in NSCLC: current evidence and future perspective. Lung Cancer Management, 2016, 5, 79-90.	1.5	1
553	Alectinib for ALK-positive non-small-cell lung cancer. Expert Review of Clinical Pharmacology, 2016, 9, 1005-1013.	1.3	17
554	Management of Resistance to Crizotinib in Anaplastic Lymphoma Kinase-Positive Non-“Small-cell Lung Cancer. Clinical Lung Cancer, 2016, 17, 474-482.	1.1	19
555	Overcoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancer. Therapeutic Advances in Medical Oncology, 2016, 8, 176-187.	1.4	25

#	ARTICLE	IF	CITATIONS
556	Second- and third-generation ALK inhibitors for non-small cell lung cancer. <i>Journal of Hematology and Oncology</i> , 2016, 9, 19.	6.9	116
557	Stratification in advanced non-small cell lung cancer: precision medicine in practice. <i>Expert Review of Precision Medicine and Drug Development</i> , 2016, 1, 279-287.	0.4	1
558	Differential Crizotinib Response Duration Among <i>ALK</i> Fusion Variants in <i>ALK</i> -Positive Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 3383-3389.	0.8	236
559	The role of phenotypic plasticity in the escape of cancer cells from targeted therapy. <i>Biochemical Pharmacology</i> , 2016, 122, 1-9.	2.0	34
560	Activation of EGFR Bypass Signaling by TGF β Overexpression Induces Acquired Resistance to Alectinib in <i>ALK</i> -Translocated Lung Cancer Cells. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 162-171.	1.9	54
561	Alectinib in <i>ALK</i> -positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 234-242.	5.1	574
563	Anaplastic Lymphoma Kinase (ALK) Signaling in Lung Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2016, 893, 179-187.	0.8	9
564	Ceritinib for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 203-214.	1.3	6
565	Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency. <i>Oncogene</i> , 2016, 35, 3854-3865.	2.6	37
566	Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 3392-3408.	2.9	217
567	Treatment modalities for advanced <i>ALK</i> -rearranged non-small-cell lung cancer. <i>Future Oncology</i> , 2016, 12, 945-961.	1.1	17
568	Antitumor activity of alectinib, a selective ALK inhibitor, in an <i>ALK</i> -positive NSCLC cell line harboring G1269A mutation. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 623-628.	1.1	23
569	Resistance mechanisms after tyrosine kinase inhibitors afatinib and crizotinib in non-small cell lung cancer, a review of the literature. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 100, 107-116.	2.0	92
570	MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations. <i>Science Translational Medicine</i> , 2016, 8, 324ra14.	5.8	81
571	Drug Resistance to EGFR Inhibitors in Lung Cancer. <i>Chemotherapy</i> , 2016, 61, 223-235.	0.8	57
572	Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 628-639.	1.9	243
573	Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs. <i>Cellular and Molecular Life Sciences</i> , 2016, 73, 1209-1224.	2.4	80
574	Non-Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases. <i>Cancer Research</i> , 2016, 76, 1506-1516.	0.4	115

#	ARTICLE	IF	CITATIONS
575	The Microenvironment of Lung Cancer and Therapeutic Implications. <i>Advances in Experimental Medicine and Biology</i> , 2016, 890, 75-110.	0.8	96
576	Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 147-157.	1.1	33
577	<i>ALK</i> inhibitors in non-small cell lung cancer: the latest evidence and developments. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 32-47.	1.4	106
578	Emerging Biomarkers in Personalized Therapy of Lung Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2016, 890, 25-36.	0.8	16
579	Resensitization to Crizotinib by the Lorlatinib <i>ALK</i> Resistance Mutation L1198F. <i>New England Journal of Medicine</i> , 2016, 374, 54-61.	13.9	433
580	Epithelial Mesenchymal Transition in Aggressive Lung Cancers. <i>Advances in Experimental Medicine and Biology</i> , 2016, 890, 37-56.	0.8	66
581	Toward a Better Understanding of the Complexity of Cancer Drug Resistance. <i>Annual Review of Pharmacology and Toxicology</i> , 2016, 56, 85-102.	4.2	261
582	A systematic analysis of the resistance and sensitivity of HER2 ^{YVMA} receptor tyrosine kinase mutant to tyrosine kinase inhibitors in HER2-positive lung cancer. <i>Journal of Receptor and Signal Transduction Research</i> , 2016, 36, 89-97.	1.3	7
583	Mutational and network level mechanisms underlying resistance to anti-cancer kinase inhibitors. <i>Seminars in Cell and Developmental Biology</i> , 2016, 50, 164-176.	2.3	31
584	<i>Biology of Lung Cancer</i> . , 2016, , 912-926.e6.		1
585	Amphiregulin triggered epidermal growth factor receptor activation confers <i>in vivo</i> crizotinib resistance of <i>EML4-ALK</i> lung cancer and circumvention by epidermal growth factor receptor inhibitors. <i>Cancer Science</i> , 2017, 108, 53-60.	1.7	28
586	ALK: a tyrosine kinase target for cancer therapy. <i>Journal of Physical Education and Sports Management</i> , 2017, 3, a001115.	0.5	131
587	Strategies to design clinical studies to identify predictive biomarkers in cancer research. <i>Cancer Treatment Reviews</i> , 2017, 53, 79-97.	3.4	80
588	Developments in pharmacotherapy for treating metastatic non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 151-163.	0.9	10
589	<i>ALK</i> gene alterations in cancer: biological aspects and therapeutic implications. <i>Pharmacogenomics</i> , 2017, 18, 277-292.	0.6	8
590	Targeting ALK: Precision Medicine Takes on Drug Resistance. <i>Cancer Discovery</i> , 2017, 7, 137-155.	7.7	405
592	Safety of alectinib for the treatment of metastatic <i>ALK</i> -rearranged non-small cell lung cancer. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 509-514.	1.0	10
593	Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition. <i>Cancer Treatment Reviews</i> , 2017, 55, 83-95.	3.4	58

#	ARTICLE	IF	CITATIONS
594	Association between PD-L1 expression and driven gene status in NSCLC: A meta-analysis. <i>European Journal of Surgical Oncology</i> , 2017, 43, 1372-1379.	0.5	29
595	Cancer genomics guide clinical practice in personalized medicine. <i>Therapie</i> , 2017, 72, 439-451.	0.6	12
596	Therapeutic strategies and mechanisms of drug resistance in anaplastic lymphoma kinase (ALK)-rearranged lung cancer. , 2017, 177, 1-8.		30
597	Characteristics and outcomes of <i>ALK</i> + non-small cell lung cancer patients in Korea. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, e239-e245.	0.7	6
598	<i>AZD</i> 0530 sensitizes drug-resistant <i>ALK</i> -positive lung cancer cells by inhibiting <i>SRC</i> signaling. <i>FEBS Open Bio</i> , 2017, 7, 472-476.	1.0	11
600	Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 713-722.	1.9	17
601	Molecular Genetics of Endometrial Carcinoma. <i>Advances in Experimental Medicine and Biology</i> , 2017, , .	0.8	6
602	Lung Cancer Biomarkers. <i>Hematology/Oncology Clinics of North America</i> , 2017, 31, 13-29.	0.9	180
603	Endometrial Carcinoma: Specific Targeted Pathways. <i>Advances in Experimental Medicine and Biology</i> , 2017, 943, 149-207.	0.8	53
604	Diagnosis and Treatment of Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2017, 31, 101-111.	0.9	32
605	Small Molecule Inhibitors of ALK. <i>Topics in Medicinal Chemistry</i> , 2017, , 435-467.	0.4	4
606	Targeted Disruption of V600E-Mutant BRAF Gene by CRISPR-Cpf1. <i>Molecular Therapy - Nucleic Acids</i> , 2017, 8, 450-458.	2.3	27
607	Targeting FBW7 as a Strategy to Overcome Resistance to Targeted Therapy in Non-Small Cell Lung Cancer. <i>Cancer Research</i> , 2017, 77, 3527-3539.	0.4	42
608	Oxidative stress mediated by nitrogen at elevated pressure inhibits non-small cell lung cancer growth. <i>Experimental Lung Research</i> , 2017, 43, 175-180.	0.5	2
609	Effects of polymorphisms identified in genome-wide association studies of never-smoking females on the prognosis of non-small cell lung cancer. <i>Cancer Genetics</i> , 2017, 212-213, 8-12.	0.2	7
610	The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy. <i>Cancer Treatment Reviews</i> , 2017, 55, 181-189.	3.4	12
611	Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer. <i>Drugs</i> , 2017, 77, 813-827.	4.9	42
612	Molecular Dynamics Validation of Crizotinib Resistance to ALK Mutations (L1196M and G1269A) and Identification of Specific Inhibitors. <i>Journal of Cellular Biochemistry</i> , 2017, 118, 3462-3471.	1.2	18

#	ARTICLE	IF	CITATIONS
613	Mechanisms of Resistance to Target Therapies in Non-small Cell Lung Cancer. Handbook of Experimental Pharmacology, 2017, 249, 63-89.	0.9	10
614	Molecular and Pharmacological Mechanisms of Drug Resistance:An Evolving Paradigm. Handbook of Experimental Pharmacology, 2017, 249, 1-12.	0.9	18
615	Clinical features of <i>Bim</i> deletion polymorphism and its relation with crizotinib primary resistance in Chinese patients with <i>ALK</i> / <i>ROS1</i> fusion-positive non-small cell lung cancer. Cancer, 2017, 123, 2927-2935.	2.0	36
616	Advancements in next-generation sequencing for diagnosis and treatment of non-small cell lung cancer. Chronic Diseases and Translational Medicine, 2017, 3, 1-7.	0.9	7
617	Mutation matters in precision medicine: A future to believe in. Cancer Treatment Reviews, 2017, 55, 136-149.	3.4	36
618	Lesion-Directed Therapies and Monitoring Tumor Evolution Using Liquid Biopsies. Cold Spring Harbor Perspectives in Medicine, 2017, 7, a029587.	2.9	15
619	Polyclonal Secondary <i>FGFR2</i> Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with <i>FGFR2</i> Fusion-Positive Cholangiocarcinoma. Cancer Discovery, 2017, 7, 252-263.	7.7	384
620	Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target. Blood, 2017, 129, 823-831.	0.6	76
621	Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer. Annals of Oncology, 2017, 28, 791-797.	0.6	178
622	Treating patients with ALK-rearranged non-small-cell lung cancer: mechanisms of resistance and strategies to overcome it. Clinical and Translational Oncology, 2017, 19, 658-666.	1.2	21
623	Understanding and targeting resistance mechanisms in NSCLC. Nature Reviews Cancer, 2017, 17, 637-658.	12.8	679
624	Exploring the crizotinib resistance mechanism of NSCLC with the L1196M mutation using molecular dynamics simulation. Journal of Molecular Modeling, 2017, 23, 323.	0.8	18
625	A reliable and stable method for determination of brigatinib in rat plasma by UPLC-MS/MS: Application to a pharmacokinetic study. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2017, 1068-1069, 84-89.	1.2	8
626	Key signaling pathways in thyroid cancer. Journal of Endocrinology, 2017, 235, R43-R61.	1.2	95
627	The role of anaplastic lymphoma kinase in pediatric cancers. Cancer Science, 2017, 108, 1913-1920.	1.7	31
628	Molecular and clinical features of second-generation anaplastic lymphoma kinase inhibitors: ceritinib. Future Oncology, 2017, 13, 2629-2644.	1.1	8
629	Lung cancer as a paradigm for precision oncology in solid tumours. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 221-233.	1.4	14
630	Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers. Molecular Cancer Therapeutics, 2017, 16, 2130-2143.	1.9	82

#	ARTICLE	IF	CITATIONS
631	Anaplastic lymphoma kinase rearrangements in non-small-cell lung cancer: novel applications in diagnostics and treatment. <i>Pharmacogenomics</i> , 2017, 18, 1179-1192.	0.6	4
632	Liquid Biopsy in Non-Small Cell Lung Cancer (NSCLC). <i>Current Clinical Pathology</i> , 2017, , 103-115.	0.0	4
633	Treatment of <i>ALK</i> -rearranged non-small cell lung cancer: A review of the landscape and approach to emerging patterns of treatment resistance in the Australian context. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, 3-13.	0.7	11
636	Combating Drug-Resistant Mutants of Anaplastic Lymphoma Kinase with Potent and Selective Type-I ^{1/2} Inhibitors by Stabilizing Unique DFG-Shifted Loop Conformation. <i>ACS Central Science</i> , 2017, 3, 1208-1220.	5.3	42
637	Effects of <i>SMYD2</i> -mediated <i>EML4</i> - <i>ALK</i> methylation on the signaling pathway and growth in non-small cell lung cancer cells. <i>Cancer Science</i> , 2017, 108, 1203-1209.	1.7	38
638	Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in <i>ALK</i> -positive Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1552-1560.	0.5	75
639	Collateral sensitivity networks reveal evolutionary instability and novel treatment strategies in <i>ALK</i> mutated non-small cell lung cancer. <i>Scientific Reports</i> , 2017, 7, 1232.	1.6	79
640	Alectinib for treatment of <i>ALK</i> -positive non-small-cell lung cancer. <i>Future Oncology</i> , 2017, 13, 321-335.	1.1	12
641	Establishment of a Conditional Transgenic Mouse Model Recapitulating <i>EML4-ALK</i> Positive Human Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 491-500.	0.5	21
642	Enigmas in tumor resistance to kinase inhibitors and calculation of the drug resistance index for cancer (DRIC). <i>Seminars in Cancer Biology</i> , 2017, 45, 36-49.	4.3	11
643	Overcoming On-Target Resistance to Tyrosine Kinase Inhibitors in Lung Cancer. <i>Annual Review of Cancer Biology</i> , 2017, 1, 257-274.	2.3	4
644	Development of crizotinib, a rationally designed tyrosine kinase inhibitor for non-small cell lung cancer. <i>International Journal of Cancer</i> , 2017, 140, 1945-1954.	2.3	19
645	Evolution from genetics to phenotype: reinterpretation of NSCLC plasticity, heterogeneity, and drug resistance. <i>Protein and Cell</i> , 2017, 8, 178-190.	4.8	22
646	Approved and Experimental Small-Molecule Oncology Kinase Inhibitor Drugs: A 2016 Overview. <i>Medicinal Research Reviews</i> , 2017, 37, 314-367.	5.0	65
647	Expanded Circulating Tumor Cells from a Patient with <i>ALK</i> -Positive Lung Cancer Present with <i>EML4-ALK</i> Rearrangement Along with Resistance Mutation and Enable Drug Sensitivity Testing: A Case Study. <i>Journal of Thoracic Oncology</i> , 2017, 12, 397-402.	0.5	37
648	The role of microRNAs in resistance to targeted treatments of non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 227-231.	1.1	35
649	Overcoming EGFR Bypass Signal-Induced Acquired Resistance to <i>ALK</i> Tyrosine Kinase Inhibitors in <i>ALK</i> -Translocated Lung Cancer. <i>Molecular Cancer Research</i> , 2017, 15, 106-114.	1.5	54
650	Drug resistance in <i>ALK</i> -positive Non-small cell lung cancer patients. <i>Seminars in Cell and Developmental Biology</i> , 2017, 64, 150-157.	2.3	21

#	ARTICLE	IF	CITATIONS
651	Histopathologic diagnosis of brain metastases: current trends in management and future considerations. <i>Brain Tumor Pathology</i> , 2017, 34, 8-19.	1.1	22
652	Effect of Food and Esomeprazole on the Pharmacokinetics of Alectinib, a Highly Selective ALK Inhibitor, in Healthy Subjects. <i>Clinical Pharmacology in Drug Development</i> , 2017, 6, 388-397.	0.8	35
653	ALK alterations and inhibition in lung cancer. <i>Seminars in Cancer Biology</i> , 2017, 42, 81-88.	4.3	33
654	Molecular Testing in Lung Cancer. , 2017, , 287-303.		2
655	Prise en charge des patients de stade avancé avec remaniement ALK : aujourd'hui et demain (À qui sera) Tj ETQq0 0 0 gBT /Over	0.8	0
656	3. Treatment Choice of ALK Inhibitor. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2017, 106, 1101-1107.	0.0	1
657	Anaplastic lymphoma tyrosine kinase oncogene in human cancer: gene aberrations, methods of detection and therapeutic potential. <i>Translational Medicine Reports</i> , 2017, 1, .	0.8	0
658	Tyrosine kinase inhibitors: new molecules in non-small cell lung cancer (EGFR AND ALK). <i>ADMET and DMPK</i> , 2017, 5, 1.	1.1	0
659	Non-small cell lung cancer treatment (r)evolution: ten years of advances and more to come. <i>Ecanermedicalscience</i> , 2017, 11, 787.	0.6	34
660	EML4-ALK Variants: Biological and Molecular Properties, and the Implications for Patients. <i>Cancers</i> , 2017, 9, 118.	1.7	147
661	Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 2047-2063.	2.0	26
662	An UPLC-MS/MS method for the quantitation of alectinib in rat plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 132, 227-231.	1.4	12
663	EGF Induced RET Inhibitor Resistance in CCDC6-RET Lung Cancer Cells. <i>Yonsei Medical Journal</i> , 2017, 58, 9.	0.9	30
664	Anaplastic Lymphoma Kinase in Cutaneous Malignancies. <i>Cancers</i> , 2017, 9, 123.	1.7	7
665	Novel Molecular Challenges in Targeting Anaplastic Lymphoma Kinase in ALK-Expressing Human Cancers. <i>Cancers</i> , 2017, 9, 148.	1.7	4
666	Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer. <i>Frontiers in Medicine</i> , 2017, 4, 39.	1.2	18
667	Resistance to mTORC1 Inhibitors in Cancer Therapy: From Kinase Mutations to Intratumoral Heterogeneity of Kinase Activity. <i>Oxidative Medicine and Cellular Longevity</i> , 2017, 2017, 1-10.	1.9	65
668	The applications of liquid biopsy in resistance surveillance of anaplastic lymphoma kinase inhibitor. <i>Cancer Management and Research</i> , 2017, Volume 9, 801-811.	0.9	14

#	ARTICLE	IF	CITATIONS
669	Adverse renal effects of anaplastic lymphoma kinase inhibitors and the response to alectinib of an ALK+ lung cancer patient with renal dysfunction. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 3211-3214.	1.0	10
670	Targeting Autophagy in ALK-Associated Cancers. <i>Cancers</i> , 2017, 9, 161.	1.7	15
671	Anaplastic lymphoma kinase inhibition in metastatic non-small cell lung cancer: clinical impact of alectinib. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 4535-4541.	1.0	27
672	Spotlight on brigatinib and its potential in the treatment of patients with metastatic ALK-positive non-small cell lung cancer who are resistant or intolerant to crizotinib. <i>Lung Cancer: Targets and Therapy</i> , 2017, Volume 8, 169-177.	1.3	8
673	Evolving Cancer Classification in the Era of Personalized Medicine: A Primer for Radiologists. <i>Korean Journal of Radiology</i> , 2017, 18, 6.	1.5	12
674	Recent advances in the management of non-small cell lung cancer. <i>F1000Research</i> , 2017, 6, 2110.	0.8	21
675	Spotlight on the treatment of ALK-rearranged non-small-cell lung cancer. <i>Lung Cancer Management</i> , 2017, 6, 125-128.	1.5	2
676	Managing Resistance to EGFR- and ALK-Targeted Therapies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 607-618.	1.8	16
677	Should aggressive thoracic therapy be performed in patients with synchronous oligometastatic non-small cell lung cancer? A meta-analysis. <i>Journal of Thoracic Disease</i> , 2017, 9, 310-317.	0.6	53
678	Recent studies move closer to answering questions about sequential therapy for anaplastic lymphoma kinase-rearranged non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2017, 9, 2847-2851.	0.6	1
679	Routine clinical use of circulating tumor cells for diagnosis of mutations and chromosomal rearrangements in non-small cell lung cancer—ready for prime-time?. <i>Translational Lung Cancer Research</i> , 2017, 6, 444-453.	1.3	12
680	New insights in non-small-cell lung cancer: circulating tumor cells and cell-free DNA. <i>Journal of Thoracic Disease</i> , 2017, 9, S1332-S1345.	0.6	13
681	5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-4-(4-((4-methylpiperazin-1-yl)methyl)-1H-1,2,3-triazol-1-yl)phenyl)pyrimidine-2, (WY-135), a novel ALK inhibitor, induces cell cycle arrest and apoptosis through inhibiting ALK and its downstream pathways in Karpas299 and H2228 cells. <i>Chemico-Biological Interactions</i> , 2018, 284, 24-31.	1.7	9
682	Drug resistance in anaplastic lymphoma kinase-rearranged lung cancer. <i>Cancer Science</i> , 2018, 109, 572-580.	1.7	49
683	The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer. <i>Future Oncology</i> , 2018, 14, 1897-1908.	1.1	5
684	ALK rearrangement in non-small cell lung cancer (NSCLC). <i>Thoracic Cancer</i> , 2018, 9, 423-430.	0.8	163
685	Autophagy modulates transforming growth factor beta 1 induced epithelial to mesenchymal transition in non-small cell lung cancer cells. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2018, 1865, 749-768.	1.9	83
686	SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors. <i>Nature Medicine</i> , 2018, 24, 512-517.	15.2	155

#	ARTICLE	IF	CITATIONS
687	Resistance of Lung Cancer to Kinase Inhibitors Specific to EGFR or ALK. Resistance To Targeted Anti-cancer Therapeutics, 2018, , 29-49.	0.1	0
688	Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound <i>ALK</i> Mutations in ALK-Positive Lung Cancer. Cancer Discovery, 2018, 8, 714-729.	7.7	228
689	Somatic genome editing with the RCAS-TVA-CRISPR-Cas9 system for precision tumor modeling. Nature Communications, 2018, 9, 1466.	5.8	52
690	Isolation and characterization of circulating melanoma cells by size filtration and fluorescent in-situ hybridization. Melanoma Research, 2018, 28, 89-95.	0.6	13
691	A secondary RET mutation in the activation loop conferring resistance to vandetanib. Nature Communications, 2018, 9, 625.	5.8	75
692	The ALK receptor in sympathetic neuron development and neuroblastoma. Cell and Tissue Research, 2018, 372, 325-337.	1.5	31
693	Established, emerging and elusive molecular targets in the treatment of lung cancer. Journal of Pathology, 2018, 244, 565-577.	2.1	15
694	Importance of protein flexibility in molecular recognition: a case study on Type-I1/2 inhibitors of ALK. Physical Chemistry Chemical Physics, 2018, 20, 4851-4863.	1.3	22
695	Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer. Annals of Oncology, 2018, 29, 872-880.	0.6	73
696	Precision medicine in ALK rearranged NSCLC: A rapidly evolving scenario. Critical Reviews in Oncology/Hematology, 2018, 122, 150-156.	2.0	36
697	Genomic heterogeneity of ALK fusion breakpoints in non-small-cell lung cancer. Modern Pathology, 2018, 31, 791-808.	2.9	79
698	The rationale for druggability of CCDC6-tyrosine kinase fusions in lung cancer. Molecular Cancer, 2018, 17, 46.	7.9	19
699	The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC). Molecular Cancer, 2018, 17, 52.	7.9	157
701	Gene Fusion in Malignant Glioma: An Emerging Target for Next-Generation Personalized Treatment. Translational Oncology, 2018, 11, 609-618.	1.7	40
702	Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK). European Journal of Medicinal Chemistry, 2018, 151, 304-314.	2.6	165
703	Background and rationale of the eXalt3 trial investigating X-396 in the treatment of ALK+ non-small-cell lung cancer. Future Oncology, 2018, 14, 1781-1787.	1.1	13
704	Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 310-320.	2.3	476
705	Discovery of Potent ALK Inhibitors Using Pharmacophore-Informatics Strategy. Cell Biochemistry and Biophysics, 2018, 76, 111-124.	0.9	21

#	ARTICLE	IF	CITATIONS
706	Scaffold hopping identifies 6,8-disubstituted purines as novel anaplastic lymphoma kinase inhibitors. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 126, 89-94.	2.0	3
707	Frontline Systemic Therapy Options in Nonsmall Cell Lung Cancer. , 2018, , 418-433.e6.		0
708	Molecular Testing in Lung Cancer. , 2018, , 164-177.e5.		0
709	Lessons To Be Learned: The Molecular Basis of Kinase-Targeted Therapies and Drug Resistance in Non-Small Cell Lung Cancer. Angewandte Chemie - International Edition, 2018, 57, 2307-2313.	7.2	36
710	Lektion gelernt? Die molekularen Grundlagen von Kinase-gerichteten Therapien und Wirkstoffresistenz im nicht-kleinzelligen Lungenkrebs. Angewandte Chemie, 2018, 130, 2329-2335.	1.6	1
711	GCC2-ALK as a targetable fusion in lung adenocarcinoma and its enduring clinical responses to ALK inhibitors. Lung Cancer, 2018, 115, 5-11.	0.9	23
712	<i>EML4-ALK</i> Variant Affects <i>ALK</i> Resistance Mutations. Journal of Clinical Oncology, 2018, 36, 1257-1259.	0.8	6
713	Emerging resistance pathways in lung cancer: what has ROS-1 taught us?. Translational Lung Cancer Research, 2018, 7, S9-S12.	1.3	3
714	Autochthonous murine models for the study of smoker and never-smoker associated lung cancers. Translational Lung Cancer Research, 2018, 7, 464-486.	1.3	11
715	The correlation between crizotinib efficacy and molecular heterogeneity by next-generation sequencing in non-small cell lung cancer. Journal of Thoracic Disease, 2018, 10, 2948-2959.	0.6	2
716	Bidirectional Adaptive Signaling between cancer and stromal cells: mechanisms and therapeutics. Expert Review of Proteomics, 2018, 15, 697-699.	1.3	1
717	Anaplastic lymphoma kinase fusions: Roles in cancer and therapeutic perspectives (Review). Oncology Letters, 2019, 17, 2020-2030.	0.8	33
718	<i>ALK</i> Fusions in Renal Cell Carcinoma: Response to Entrectinib. JCO Precision Oncology, 2018, 2, 1-8.	1.5	16
719	Anaplastic Lymphoma Kinase (ALK) Receptor Tyrosine Kinase: A Catalytic Receptor with Many Faces. International Journal of Molecular Sciences, 2018, 19, 3448.	1.8	45
720	Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma. Drug Design, Development and Therapy, 2018, Volume 12, 3549-3561.	2.0	35
721	Heat shock protein 90 inhibitors overcome the resistance to Fms-like tyrosine kinase 3 inhibitors in acute myeloid leukemia. Oncotarget, 2018, 9, 34240-34258.	0.8	18
722	Integrated proximal proteomics reveals IRS2 as a determinant of cell survival in ALK-driven neuroblastoma. Science Signaling, 2018, 11, .	1.6	33
723	Ceritinib for an anaplastic lymphoma kinase rearrangement-positive patient previously treated with alectinib with poor performance status. OncoTargets and Therapy, 2018, Volume 12, 15-19.	1.0	1

#	ARTICLE	IF	CITATIONS
724	Cystic brain metastases in ALK-rearranged non-small cell lung cancer. <i>Ecancermedicalsecience</i> , 2018, 12, 818.	0.6	3
725	Generation and characterization of MEK and ERK inhibitors- resistant non-small-cells-lung-cancer (NSCLC) cells. <i>BMC Cancer</i> , 2018, 18, 1028.	1.1	7
726	A case of ALK-rearranged non-small cell lung cancer that responded to ceritinib after development of resistance to alectinib. <i>Oncotarget</i> , 2018, 9, 23315-23319.	0.8	7
727	Insight into resistance mechanism of anaplastic lymphoma kinase to alectinib and JH-VIII-157-02 caused by G1202R solvent front mutation. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 1183-1193.	2.0	6
728	A Convergence-Based Framework for Cancer Drug Resistance. <i>Cancer Cell</i> , 2018, 33, 801-815.	7.7	181
729	A successful pembrolizumab treatment case of lung adenocarcinoma after becoming resistant to ALK-TKI treatment due to G1202R mutation. <i>Respiratory Investigation</i> , 2018, 56, 365-368.	0.9	5
730	Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations. <i>Nature</i> , 2018, 559, 125-129.	13.7	223
731	Small Molecules in Oncology. <i>Recent Results in Cancer Research</i> , 2018, , .	1.8	5
732	Crizotinib. <i>Recent Results in Cancer Research</i> , 2018, 211, 57-65.	1.8	40
733	Exploiting vulnerabilities in cancer signalling networks to combat targeted therapy resistance. <i>Essays in Biochemistry</i> , 2018, 62, 583-593.	2.1	25
735	Acquired resistance in oncogene-addicted non-small-cell lung cancer. <i>Future Oncology</i> , 2018, 14, 29-40.	1.1	18
736	Structure and energy based quantitative missense variant effect analysis provides insights into drug resistance mechanisms of anaplastic lymphoma kinase mutations. <i>Scientific Reports</i> , 2018, 8, 10664.	1.6	13
737	Oncogene addicted non-small-cell lung cancer: current standard and hot topics. <i>Future Oncology</i> , 2018, 14, 3-17.	1.1	18
738	Current Molecular-Targeted Therapies in NSCLC and Their Mechanism of Resistance. <i>Cancers</i> , 2018, 10, 224.	1.7	95
739	Next generation sequencing reveals a novel ALK G1128A mutation resistant to crizotinib in an ALK-Rearranged NSCLC patient. <i>Lung Cancer</i> , 2018, 123, 83-86.	0.9	19
740	Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib. <i>Nature Medicine</i> , 2018, 24, 1167-1177.	15.2	157
741	Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes. <i>Cancers</i> , 2018, 10, 62.	1.7	73
742	Role and targeting of anaplastic lymphoma kinase in cancer. <i>Molecular Cancer</i> , 2018, 17, 30.	7.9	71

#	ARTICLE	IF	CITATIONS
743	Personalized medicine in non-small cell lung cancer: a review from a pharmacogenomics perspective. <i>Acta Pharmaceutica Sinica B</i> , 2018, 8, 530-538.	5.7	43
744	Exposure-response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 129-138.	1.1	25
745	Latest perspectives of orally bioavailable 2,4-diarylaminopyrimidine analogues (DAAPalogues) as anaplastic lymphoma kinase inhibitors: discovery and clinical developments. <i>RSC Advances</i> , 2018, 8, 16470-16493.	1.7	5
746	Reviving B-Factors: Activating ALK Mutations Increase Protein Dynamics of the Unphosphorylated Kinase. <i>ACS Medicinal Chemistry Letters</i> , 2018, 9, 872-877.	1.3	9
747	Overcoming resistance in non-small cell lung cancer: A practical lesson for the medicinal chemist. <i>Archiv Der Pharmazie</i> , 2018, 351, e1800037.	2.1	9
748	Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 694-708.	12.5	255
749	Targeting phosphoinositide 3-kinase (PI3K) in head and neck squamous cell carcinoma (HNSCC). <i>Cancers of the Head & Neck</i> , 2018, 3, 3.	6.2	58
750	Challenges in ALK inhibition of ALK-positive non-small-cell lung cancer: from ALK positivity detection to treatment strategies after relapse. <i>Future Oncology</i> , 2018, 14, 2303-2317.	1.1	6
751	Systemic Treatment of Chest Tumors: Highlighting Some Differences Between Eastern and Western Countries. <i>Current Cancer Therapy Reviews</i> , 2018, 14, 120-136.	0.2	0
752	Development and Verification of an RNA Sequencing (RNA-Seq) Assay for the Detection of Gene Fusions in Tumors. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 495-511.	1.2	36
753	Reviving B-Factors: Retrospective Normalized B-Factor Analysis of c-ros Oncogene 1 Receptor Tyrosine Kinase and Anaplastic Lymphoma Kinase L1196M with Crizotinib and Lorlatinib. <i>ACS Medicinal Chemistry Letters</i> , 2018, 9, 878-883.	1.3	13
754	Clinical Pharmacokinetics of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer. <i>Clinical Pharmacokinetics</i> , 2019, 58, 403-420.	1.6	31
755	Drug Discovery Targeting Anaplastic Lymphoma Kinase (ALK). <i>Journal of Medicinal Chemistry</i> , 2019, 62, 10927-10954.	2.9	80
756	Opportunities of circulating tumor DNA in lung cancer. <i>Cancer Treatment Reviews</i> , 2019, 78, 31-41.	3.4	16
757	Targeted Therapies in Lung Cancer: Management Strategies for Nurses and Practitioners. , 2019, , .		0
758	Proximity proteomics identifies cancer cell membrane cis-molecular complex as a potential cancer target. <i>Cancer Science</i> , 2019, 110, 2607-2619.	1.7	10
759	Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells. <i>Frontiers in Oncology</i> , 2019, 9, 579.	1.3	24
760	ATP-Competitive Inhibitors Midostaurin and Avapritinib Have Distinct Resistance Profiles in Exon 17 Mutant KIT. <i>Cancer Research</i> , 2019, 79, 4283-4292.	0.4	21

#	ARTICLE	IF	CITATIONS
761	Discovery of 2-aminopyridines bearing a pyridone moiety as potent ALK inhibitors to overcome the crizotinib-resistant mutants. <i>European Journal of Medicinal Chemistry</i> , 2019, 183, 111734.	2.6	10
762	An exploration of solvent-front region high affinity moiety leading to novel potent ALK & ROS1 dual inhibitors with mutant-combating effects. <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 115051.	1.4	8
763	ALK mutation dynamics and clonal evolution in a neuroblastoma model exhibiting two ALK mutations. <i>Oncotarget</i> , 2019, 10, 4937-4950.	0.8	5
764	Precision Oncologyâ€”The Quest for Evidence. <i>Journal of Personalized Medicine</i> , 2019, 9, 43.	1.1	13
765	Progress on small-molecule proteolysis-targeting chimeras. <i>Future Medicinal Chemistry</i> , 2019, 11, 2715-2734.	1.1	8
766	Targeting the Complement Pathway as a Therapeutic Strategy in Lung Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 954.	2.2	89
767	End-Point Binding Free Energy Calculation with MM/PBSA and MM/GBSA: Strategies and Applications in Drug Design. <i>Chemical Reviews</i> , 2019, 119, 9478-9508.	23.0	1,064
768	Advanced Nonâ€”Small Cell Lung Cancer: Sequencing Agents in the EGFR-Mutated/ALK-Rearranged Populations. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, e187-e197.	1.8	33
769	Clinical Validation of a Cell-Free DNA Gene Panel. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 632-645.	1.2	15
770	Clinical features and outcomes of <i>ALK</i> rearranged nonâ€”small cell lung cancer with primary resistance to crizotinib. <i>Thoracic Cancer</i> , 2019, 10, 1213-1219.	0.8	5
771	Emerging therapies for non-small cell lung cancer. <i>Journal of Hematology and Oncology</i> , 2019, 12, 45.	6.9	111
772	Relevance of Detection of Mechanisms of Resistance to ALK Inhibitors in ALK-Rearranged NSCLC in Routine Practice. <i>Clinical Lung Cancer</i> , 2019, 20, 297-304.e1.	1.1	14
773	Identification of mutations associated with acquired resistance to sunitinib in renal cell cancer. <i>International Journal of Cancer</i> , 2019, 145, 1991-2001.	2.3	32
774	Discovery of novel mutant-combating ALK and ROS1 dual inhibitors bearing imidazolidin-2-one moiety with reasonable PK properties. <i>European Journal of Medicinal Chemistry</i> , 2019, 171, 297-309.	2.6	13
775	Insight on mutationâ€”induced resistance to anaplastic lymphoma kinase inhibitor ceritinib from molecular dynamics simulations. <i>Biopolymers</i> , 2019, 110, e23257.	1.2	4
776	Driver network as a biomarker: systematic integration and network modeling of multi-omics data to derive driver signaling pathways for drug combination prediction. <i>Bioinformatics</i> , 2019, 35, 3709-3717.	1.8	50
777	Clinical development of targeted and immune based anti-cancer therapies. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 156.	3.5	170
778	Diff-Quik Cytology Smears from Endobronchial Ultrasound Transbronchial Needle Aspiration Lymph Node Specimens as a Source of DNA for Next-Generation Sequencing Instead of Cell Blocks. <i>Respiration</i> , 2019, 97, 525-539.	1.2	25

#	ARTICLE	IF	CITATIONS
779	Targeting anaplastic lymphoma kinase in neuroblastoma. <i>Apmis</i> , 2019, 127, 288-302.	0.9	53
780	Circulating tumor cells (CTCs) for the noninvasive monitoring and personalization of non-small cell lung cancer (NSCLC) therapies. <i>Journal of Thoracic Disease</i> , 2019, 11, S45-S56.	0.6	28
781	An Overview, Current Challenges of Drug Resistance, and Targeting Metastasis Associated With Lung Cancer. , 2019, , 21-38.		1
782	A Case of Ovarian Metastasis from ALK-rearranged Lung Adenocarcinoma in an Elderly Woman Who Resumed Menstruation due to Estradiol Production. <i>Japanese Journal of Lung Cancer</i> , 2019, 59, 254-259.	0.0	0
783	PROTACs: great opportunities for academia and industry. <i>Signal Transduction and Targeted Therapy</i> , 2019, 4, 64.	7.1	367
784	Treatment of ALK-rearranged non-small-cell lung cancer with brigatinib as second or later lines. <i>Anti-Cancer Drugs</i> , 2019, 30, 740-744.	0.7	7
785	Pleural Fluid for the Detection of Actionable Somatic Mutations. <i>Journal of Bronchology and Interventional Pulmonology</i> , 2019, 26, 78-80.	0.8	0
787	Metabolic Remodelling: An Accomplice for New Therapeutic Strategies to Fight Lung Cancer. <i>Antioxidants</i> , 2019, 8, 603.	2.2	12
788	Repotrectinib (TPX-0005), effectively reduces growth of ALK driven neuroblastoma cells. <i>Scientific Reports</i> , 2019, 9, 19353.	1.6	19
789	Mechanisms of suppression of cell growth by dual inhibition of ALK and MEK in ALK-positive non-small cell lung cancer. <i>Scientific Reports</i> , 2019, 9, 18842.	1.6	19
790	New generation anaplastic lymphoma kinase inhibitors. <i>Translational Lung Cancer Research</i> , 2019, 8, S280-S289.	1.3	14
791	Alectinib, an anaplastic lymphoma kinase (ALK) inhibitor, as a bridge to allogeneic stem cell transplantation in a patient with ALK-positive anaplastic large-cell lymphoma refractory to chemotherapy and brentuximab vedotin. <i>Clinical Case Reports (discontinued)</i> , 2019, 7, 2500-2504.	0.2	6
792	Alectinib Resistance in ALK-Rearranged Lung Cancer by Dual Salvage Signaling in a Clinically Paired Resistance Model. <i>Molecular Cancer Research</i> , 2019, 17, 212-224.	1.5	41
793	Molecular inhibitory mechanism study on the potent inhibitor brigatinib against four crizotinib-resistant ALK mutations. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 562-574.	1.2	6
794	New insights into designing hybrid nanoparticles for lung cancer: Diagnosis and treatment. <i>Journal of Controlled Release</i> , 2019, 295, 250-267.	4.8	119
795	Discovery of fluorescent 3-heteroaryl coumarin derivatives as novel inhibitors of anaplastic lymphoma kinase. <i>Organic and Biomolecular Chemistry</i> , 2019, 17, 186-194.	1.5	12
796	Concurrent Single-Cell RNA and Targeted DNA Sequencing on an Automated Platform for Comeasurement of Genomic and Transcriptomic Signatures. <i>Clinical Chemistry</i> , 2019, 65, 272-281.	1.5	25
797	Aiding and Abetting: How the Tumor Microenvironment Protects Cancer from Chemotherapy. <i>Annual Review of Cancer Biology</i> , 2019, 3, 409-428.	2.3	13

#	ARTICLE	IF	CITATIONS
798	Resistance to molecularly targeted therapy in non-small-cell lung cancer. <i>Respiratory Investigation</i> , 2019, 57, 20-26.	0.9	46
799	Activation of IGF-1R pathway and NPM-ALK G1269A mutation confer resistance to crizotinib treatment in NPM-ALK positive lymphoma. <i>Investigational New Drugs</i> , 2020, 38, 599-609.	1.2	10
800	Differences Between the East and the West in Managing Advanced-Stage Non-small Cell Lung Cancer. <i>Clinical Oncology</i> , 2020, 32, e1-e9.	0.6	6
801	Designing clinical studies for biomarker discovery: The Design criteria. , 2020, , 441-466.		0
802	Tumour evolution in hepatocellular carcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 139-152.	8.2	501
803	Acquired Resistance in Lung Cancer. <i>Annual Review of Cancer Biology</i> , 2020, 4, 279-297.	2.3	13
804	Establishment and application of a method of next generation sequencing of 285 genes in lung cancer based on Ion-Proton platform. <i>Translational Cancer Research</i> , 2020, 9, 4239-4249.	0.4	0
805	Chemical strategies to overcome resistance against targeted anticancer therapeutics. <i>Nature Chemical Biology</i> , 2020, 16, 817-825.	3.9	41
806	Tyrosine Kinase Receptors in Oncology. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8529.	1.8	46
807	Surgical Management of Stage IIIA Non-small Cell Lung Cancer. <i>Current Pulmonology Reports</i> , 2020, 9, 151-163.	0.5	0
808	Novel ALK mutation with durable response to brigatinib—a case report. <i>Translational Lung Cancer Research</i> , 2020, 9, 2145-2148.	1.3	2
809	Phase 1/2 study of ceritinib in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non-small cell lung cancer previously treated with crizotinib: Results from ASCEND-6. <i>Lung Cancer</i> , 2020, 150, 240-246.	0.9	10
810	First line Immunotherapy for Non-Small Cell Lung Cancer. <i>Pharmaceuticals</i> , 2020, 13, 373.	1.7	49
811	CD30 and ALK combination therapy has high therapeutic potency in RANBP2-ALK-rearranged epithelioid inflammatory myofibroblastic sarcoma. <i>British Journal of Cancer</i> , 2020, 123, 1101-1113.	2.9	17
812	ALK Inhibitors Do Not Increase Sensitivity to Radiation in EML4-ALK Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2020, 40, 4937-4946.	0.5	7
814	Making NSCLC Crystal Clear: How Kinase Structures Revolutionized Lung Cancer Treatment. <i>Crystals</i> , 2020, 10, 725.	1.0	4
815	Prolonged survival without progression under crizotinib treatment. <i>Cancer Treatment and Research Communications</i> , 2020, 25, 100259.	0.7	1
816	Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 10726-10741.	2.9	30

#	ARTICLE	IF	CITATIONS
817	Anaplastic Lymphoma Kinase Mutationâ€“Positive Nonâ€“Small Cell Lung Cancer. Thoracic Surgery Clinics, 2020, 30, 137-146.	0.4	8
818	Advances in Treatment of Locally Advanced or Metastatic Nonâ€“Small Cell Lung Cancer. Clinics in Chest Medicine, 2020, 41, 223-235.	0.8	18
819	Non-Small Cell Lung Cancer from Genomics to Therapeutics: A Framework for Community Practice Integration to Arrive at Personalized Therapy Strategies. Journal of Clinical Medicine, 2020, 9, 1870.	1.0	16
820	The Use of Three-Dimensional DNA Fluorescent In Situ Hybridization (3D DNA FISH) for the Detection of Anaplastic Lymphoma Kinase (ALK) in Non-Small Cell Lung Cancer (NSCLC) Circulating Tumor Cells. Cells, 2020, 9, 1465.	1.8	14
821	Clinical utility of liquid biopsy for the diagnosis and monitoring of <i>EML4-ALK</i> NSCLC patients. Advances in Laboratory Medicine / Avances En Medicina De Laboratorio, 2020, 1, .	0.1	0
822	Lorlatinib for the treatment of <i>ALK</i>-positive metastatic non-small cell lung cancer. Expert Review of Anticancer Therapy, 2020, 20, 233-240.	1.1	12
823	Anaplastic lymphoma kinase inhibitors: an updated patent review (2014â€“2018). Expert Opinion on Therapeutic Patents, 2020, 30, 351-373.	2.4	6
824	Frontiers of ctDNA, targeted therapies, and immunotherapy in non-small-cell lung cancer. Translational Lung Cancer Research, 2020, 9, 111-138.	1.3	27
825	<p>ALK Rearrangement Adenocarcinoma with Histological Transformation to Squamous Cell Carcinoma Resistant to Alectinib and Ceritinib<p>. OncoTargets and Therapy, 2020, Volume 13, 1557-1560.	1.0	16
826	CT-Based Radiomic Signature as a Prognostic Factor in Stage IV ALK-Positive Non-small-cell Lung Cancer Treated With TKI Crizotinib: A Proof-of-Concept Study. Frontiers in Oncology, 2020, 10, 57.	1.3	32
827	The cytochrome P450 metabolic profiling of SMU-B in vitro, a novel small molecule tyrosine kinase inhibitor. Journal of Pharmaceutical and Biomedical Analysis, 2020, 188, 113400.	1.4	2
828	Dual-molecular barcode sequencing detects rare variants in tumor and cell free DNA in plasma. Scientific Reports, 2020, 10, 3391.	1.6	24
829	Light-induced control of protein destruction by opto-PROTAC. Science Advances, 2020, 6, eaay5154.	4.7	139
830	Drug resistance mechanisms in Japanese anaplastic lymphoma kinaseâ€“positive nonâ€“small cell lung cancer and the clinical responses based on the resistant mechanisms. Cancer Science, 2020, 111, 932-939.	1.7	39
831	The Evolving Diagnostic and Treatment Landscape of NTRK-Fusion-Driven Pediatric Cancers. Paediatric Drugs, 2020, 22, 189-197.	1.3	18
832	Systematic review of neurotrophic tropomyosin-related kinase inhibition as a tumor-agnostic management strategy. Future Oncology, 2020, 16, 61-74.	1.1	7
833	Clinical consequences of resistance to ALK inhibitors in non-small cell lung cancer. Expert Review of Respiratory Medicine, 2020, 14, 385-390.	1.0	6
835	Inhibition of Mitogen-Activated Protein Kinase Kinase Alone and in Combination with Anaplastic Lymphoma Kinase (ALK) Inhibition Suppresses Tumor Growth in a Mouse Model of ALK-Positive Lung Cancer. Journal of Pharmacology and Experimental Therapeutics, 2020, 374, 134-140.	1.3	4

#	ARTICLE	IF	CITATIONS
836	Revealing Acquired Resistance Mechanisms of Kinase-Targeted Drugs Using an on-the-Fly, Function-Site Interaction Fingerprint Approach. <i>Journal of Chemical Theory and Computation</i> , 2020, 16, 3152-3161.	2.3	8
837	Non-Coding RNAs in Lung Tumor Initiation and Progression. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2774.	1.8	27
838	EML4-ALK V3 oncogenic fusion proteins promote microtubule stabilization and accelerated migration through NEK9 and NEK7. <i>Journal of Cell Science</i> , 2020, 133, .	1.2	30
839	Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells. <i>Cancers</i> , 2020, 12, 927.	1.7	6
840	Small-molecule PROTACs: novel agents for cancer therapy. <i>Future Medicinal Chemistry</i> , 2020, 12, 915-938.	1.1	19
841	Landscape of drug-resistance mutations in kinase regulatory hotspots. <i>Briefings in Bioinformatics</i> , 2021, 22, .	3.2	15
842	The novel ALK inhibitor ZX-29 induces apoptosis through inhibiting ALK and inducing ROS-mediated endoplasmic reticulum stress in Karpas299 cells. <i>Journal of Biochemical and Molecular Toxicology</i> , 2021, 35, e22666.	1.4	4
843	SAF-189s, a potent new-generation ROS1 inhibitor, is active against crizotinib-resistant ROS1 mutant-driven tumors. <i>Acta Pharmacologica Sinica</i> , 2021, 42, 998-1004.	2.8	11
844	Multiple mutations within individual oncogenes. <i>Cancer Science</i> , 2021, 112, 483-489.	1.7	10
845	Resistance mechanisms to ALK TKIs in tumors other than lung cancer. , 2021, , 101-121.		0
846	Cell-Free Circulating Tumor DNA Improves Standard Genotyping of Non-Small-Cell Lung Cancer and Increases Detection of Targetable Alterations in a Selected Hispanic Cohort. <i>Oncology</i> , 2021, 99, 539-546.	0.9	3
847	Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer. <i>Nature Communications</i> , 2021, 12, 1261.	5.8	52
848	Immunotherapy for ALK-Rearranged Non-Small Cell Lung Cancer: Challenges Inform Promising Approaches. <i>Cancers</i> , 2021, 13, 1476.	1.7	21
849	Identification of Novel Alectinib-Resistant ALK Mutation G1202K with Sensitization to Lorlatinib: A Case Report and in silico Structural Modelling. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 2131-2138.	1.0	7
850	ALK Inhibitors in Nonsmall Cell Lung Cancer. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2021, 42, 067-070.	0.1	0
851	Efficacy of combination treatment using YHO-1701, an orally active STAT3 inhibitor, with molecular-targeted agents on cancer cell lines. <i>Scientific Reports</i> , 2021, 11, 6685.	1.6	8
852	A Case of Small Cell Lung Carcinoma Harboring an EML4-ALK Fusion with Partial Response to Crizotinib. <i>Clinical Lung Cancer</i> , 2021, 22, e799-e803.	1.1	2
853	Second allogeneic transplantation using umbilical cord blood for a patient with relapsed ALK+ anaplastic large cell lymphoma after allogeneic bone marrow transplantation in the era of ALK inhibitors. <i>Medicine (United States)</i> , 2021, 100, e25576.	0.4	2

#	ARTICLE	IF	CITATIONS
854	Small Molecules in the Treatment of Squamous Cell Carcinomas: Focus on Indirubins. <i>Cancers</i> , 2021, 13, 1770.	1.7	15
855	Stem cells and lung cancer. , 2021, , 340-352.		1
856	Intratumoral Cellular Heterogeneity: Implications for Drug Resistance in Patients with Non-Small Cell Lung Cancer. <i>Cancers</i> , 2021, 13, 2023.	1.7	8
857	Updates in Pharmacogenetics of Non-Small Cell Lung Cancer. , 0, , .		2
858	Impact of ALK Inhibitors in Patients With <i>ALK</i> -Rearranged Nonlung Solid Tumors. <i>JCO Precision Oncology</i> , 2021, 5, 756-766.	1.5	16
859	Combining Radiation Therapy with ALK Inhibitors in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer (NSCLC): A Clinical and Preclinical Overview. <i>Cancers</i> , 2021, 13, 2394.	1.7	6
860	Lung Cancer Prediction using Machine Learning. <i>International Journal of Advanced Research in Science, Communication and Technology</i> , 0, , 21-27.	0.0	0
861	An insight into lung cancer: a comprehensive review exploring ALK TKI and mechanisms of resistance. <i>Bosnian Journal of Basic Medical Sciences</i> , 2021, , .	0.6	4
862	Cancer Selective Target Degradation by Folate-Caged PROTACs. <i>Journal of the American Chemical Society</i> , 2021, 143, 7380-7387.	6.6	117
863	The Role of Tumor Inflammatory Microenvironment in Lung Cancer. <i>Frontiers in Pharmacology</i> , 2021, 12, 688625.	1.6	79
864	Development of Alectinib-Based PROTACs as Novel Potent Degraders of Anaplastic Lymphoma Kinase (ALK). <i>Journal of Medicinal Chemistry</i> , 2021, 64, 9120-9140.	2.9	33
865	Monitoring therapeutic response and resistance with liquid biopsy. <i>Precision Cancer Medicine</i> , 0, 4, 15-15.	1.8	0
866	The mechanisms of resistance to second- and third-generation ALK inhibitors and strategies to overcome such resistance. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 975-988.	1.1	10
867	Guidelines for clinical practice of ALK fusion detection in non-small-cell lung cancer: a proposal from the Chinese RATICAL study group. <i>Journal of the National Cancer Center</i> , 2021, 1, 123-131.	3.0	5
868	ALK-Positive Non-Small Cell Lung Cancer; Potential Combination Drug Treatments. <i>Current Cancer Drug Targets</i> , 2021, 21, 737-748.	0.8	5
869	Actionability of on-target ALK Resistance Mutations in Patients With Non-Small Cell Lung Cancer: Local Experience and Review of the Literature. <i>Clinical Lung Cancer</i> , 2022, 23, e104-e115.	1.1	13
870	Exceptional response to the ALK and ROS1 inhibitor lorlatinib and subsequent mechanism of resistance in relapsed <i>ALK</i> F1174L-mutated neuroblastoma. <i>Journal of Physical Education and Sports Management</i> , 2021, 7, a006064.	0.5	16
871	Sustained response to brigatinib in a patient with refractory metastatic pheochromocytoma harboring R1192P anaplastic lymphoma kinase mutation: a case report from the Austrian Group Medical Tumor Therapy next-generation sequencing registry and discussion of the literature. <i>ESMO Open</i> , 2021, 6, 100233.	2.0	4

#	ARTICLE	IF	CITATIONS
872	Research Progress on the Drug Resistance of ALK Kinase Inhibitors. <i>Current Medicinal Chemistry</i> , 2022, 29, 2456-2475.	1.2	3
873	Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism in <i>BRAF</i> -Mutated Multiple Myeloma. <i>Clinical Cancer Research</i> , 2021, 27, 6432-6444.	3.2	18
874	Identifying transcriptional programs underlying cancer drug response with TraCe-seq. <i>Nature Biotechnology</i> , 2022, 40, 86-93.	9.4	23
875	Clinicopathological and prognostic implications of <i>ALK</i> rearrangement in patients with completely surgically resected lung adenocarcinoma. <i>Thoracic Cancer</i> , 2021, 12, 3011-3018.	0.8	4
876	Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing. <i>European Journal of Cancer</i> , 2021, 156, 1-11.	1.3	24
877	The Resistance Mechanisms and Treatment Strategies for <i>ALK</i> -Rearranged Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 713530.	1.3	54
878	Resistance to anaplastic lymphoma kinase (<i>ALK</i>) tyrosine kinase inhibitors (TKIs) in patients with lung cancer: Single mutations, compound mutations, and other mechanisms of drug resistance. , 2021, , 87-99.		1
879	Therapeutic strategies to overcome <i>ALK</i> resistance in lung cancer. , 2021, , 123-139.		0
880	State of the art and future perspectives. , 2021, , 177-190.		0
881	<i>NPM-ALK</i> : A Driver of Lymphoma Pathogenesis and a Therapeutic Target. <i>Cancers</i> , 2021, 13, 144.	1.7	11
882	Crizotinib for recurring non-small-cell lung cancer with <i>EML4-ALK</i> fusion genes previously treated with alectinib: A phase II trial. <i>Thoracic Cancer</i> , 2021, 12, 643-649.	0.8	5
883	Immune Resistance in Lung Adenocarcinoma. <i>Cancers</i> , 2021, 13, 384.	1.7	82
884	Integrating Omics Data for Quantitative and Systems Pharmacology in Translational Oncology. , 2013, , 187-206.		1
885	Clinical Implications of Epigenetic Alterations in Human Thoracic Malignancies: Epigenetic Alterations in Lung Cancer. <i>Methods in Molecular Biology</i> , 2012, 863, 221-239.	0.4	7
886	Resistance to Anti-Cancer Therapeutics. , 2019, , 65-82.		1
887	Genomic Applications in Pulmonary Malignancies. , 2019, , 363-392.		1
888	Genomic Pathology of Lung Cancer. , 2013, , 1-46.		1
890	Acquired Resistance to Targeted Therapies in Advanced Non-Small Cell Lung Cancer: New Strategies and New Agents. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, 33, e272-e278.	1.8	12

#	ARTICLE	IF	CITATIONS
891	Inhibiting the Phosphoinositide 3-Kinase/AKT/Mammalian Target of Rapamycin Pathway. , 2013, , 99-132.		1
892	Metastatic Anaplastic Lymphoma Kinase-1 (ALK-1)-Rearranged Inflammatory Myofibroblastic Sarcoma to the Brain with Leptomeningeal Involvement: Favorable Response to Serial ALK Inhibitors: A Case Report. American Journal of Case Reports, 2017, 18, 799-804.	0.3	22
893	Customised , Individualised Treatment of Metastatic Non-Small-Cell Lung Carcinoma (NSCLC) = ØšÙ,,Ø¹Ù,,ØšØ- ØšÙ,,ÙØ±Ø-Ùš Ùr Øš Sultan Qaboos University Medical Journal, 2013, 13, 202-217.	0.3	8
894	Crizotinib: ALK/Met inhibitor, oncolytic. Drugs of the Future, 2011, 36, 91.	0.0	13
895	Complex Mutations & Subpopulations of Deletions at Exon 19 of EGFR in NSCLC Revealed by Next Generation Sequencing: Potential Clinical Implications. PLoS ONE, 2012, 7, e42164.	1.1	51
896	Drug Resistance Missense Mutations in Cancer Are Subject to Evolutionary Constraints. PLoS ONE, 2013, 8, e82059.	1.1	26
897	Genomic Aberrations in Crizotinib Resistant Lung Adenocarcinoma Samples Identified by Transcriptome Sequencing. PLoS ONE, 2016, 11, e0153065.	1.1	18
898	Epidermal Growth Factor Receptor Mutation and Anaplastic Lymphoma Kinase Gene Fusion: Detection in Malignant Pleural Effusion by RNA or PNA Analysis. PLoS ONE, 2016, 11, e0158125.	1.1	18
899	Sensitivity Analysis of the NPM-ALK Signalling Network Reveals Important Pathways for Anaplastic Large Cell Lymphoma Combination Therapy. PLoS ONE, 2016, 11, e0163011.	1.1	14
900	The Role of Anaplastic Lymphoma Kinase in Human Cancers. Oncology & Hematology Review, 2013, 09, 149.	0.2	4
901	ALK-rearrangements and testing methods in non-small cell lung cancer: a review. Genes and Cancer, 2014, 5, 1-14.	0.6	54
902	Targeting SALL4 by entinostat in lung cancer. Oncotarget, 2016, 7, 75425-75440.	0.8	29
903	Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells. Oncotarget, 2014, 5, 4920-4928.	0.8	46
904	Epitope mapping of spontaneous autoantibodies to anaplastic lymphoma kinase (ALK) in non-small cell lung cancer. Oncotarget, 2017, 8, 92265-92274.	0.8	17
905	Targeted drugs for systemic therapy of lung cancer with brain metastases. Oncotarget, 2018, 9, 5459-5472.	0.8	47
906	Overcoming drug-tolerant cancer cell subpopulations showing AXL activation and epithelial-mesenchymal transition is critical in conquering ALK-positive lung cancer. Oncotarget, 2018, 9, 27242-27255.	0.8	31
907	NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922. Oncotarget, 2015, 6, 5720-5734.	0.8	29
908	Targeting autophagy enhances the anti-tumoral action of crizotinib in ALK-positive anaplastic large cell lymphoma. Oncotarget, 2015, 6, 30149-30164.	0.8	43

#	ARTICLE	IF	CITATIONS
909	Targeting stemness is an effective strategy to control <i>EML4-ALK</i> + non-small cell lung cancer cells. <i>Oncotarget</i> , 2015, 6, 40255-40267.	0.8	17
910	Growth-stimulatory activity of TIMP-2 is mediated through c-Src activation followed by activation of FAK, PI3-kinase/AKT, and ERK1/2 independent of MMP inhibition in lung adenocarcinoma cells. <i>Oncotarget</i> , 2015, 6, 42905-42922.	0.8	22
911	Crizotinib induces autophagy through inhibition of the STAT3 pathway in multiple lung cancer cell lines. <i>Oncotarget</i> , 2015, 6, 40268-40282.	0.8	47
912	Metformin restores crizotinib sensitivity in crizotinib-resistant human lung cancer cells through inhibition of IGF1-R signaling pathway. <i>Oncotarget</i> , 2016, 7, 34442-34452.	0.8	41
913	Drug resistance to EGFR tyrosine kinase inhibitors for non-small cell lung cancer. <i>Acta Medica Okayama</i> , 2014, 68, 191-200.	0.1	15
914	Treating ALK-positive non-small cell lung cancer. <i>Annals of Translational Medicine</i> , 2018, 6, 141-141.	0.7	23
915	Emerging application of genomics-guided therapeutics in personalized lung cancer treatment. <i>Annals of Translational Medicine</i> , 2018, 6, 160-160.	0.7	22
916	A crowded, but still varied, space: brigatinib in anaplastic lymphoma kinase-rearranged non-small cell lung cancer. <i>Translational Cancer Research</i> , 2017, 6, S78-S82.	0.4	8
917	How to select the best upfront therapy for metastatic disease? Focus on ALK-rearranged non-small cell lung cancer (NSCLC). <i>Translational Lung Cancer Research</i> , 2020, 9, 2521-2534.	1.3	15
918	Overcoming TKI resistance in fusion-driven NSCLC: new generation inhibitors and rationale for combination strategies. <i>Translational Lung Cancer Research</i> , 2020, 9, 2581-2598.	1.3	11
919	Biomarkers for the targeted therapies of non-small cell lung cancer. <i>Current Biomarker Findings</i> , 0, , 7.	0.4	3
920	Genotype Driven Therapy for Non-Small Cell Lung Cancer: Resistance, Pan Inhibitors and Immunotherapy. <i>Current Medicinal Chemistry</i> , 2020, 27, 5274-5316.	1.2	28
921	Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer. <i>Current Cancer Drug Targets</i> , 2019, 19, 595-630.	0.8	61
922	A Computer - Aided Drug Designing for Pharmacological Inhibition of Mutant ALK for the Treatment of Non-small Cell Lung Cancer. <i>Current Topics in Medicinal Chemistry</i> , 2019, 19, 1129-1144.	1.0	16
923	Achievements in Cancer Research and its Therapeutics in Hundred Years. <i>Current Topics in Medicinal Chemistry</i> , 2019, 19, 1545-1562.	1.0	2
924	EML4-ALK in non-small-cell lung cancer: the breathtaking progress from benchtop to Phase III clinical trial. <i>Therapy: Open Access in Clinical Medicine</i> , 2011, 8, 55-61.	0.2	1
925	A Case of ALK-rearranged Squamous Cell Lung Cancer Accompanied by Severe Liver Dysfunction Caused by Crizotinib but Not Alectinib. <i>Japanese Journal of Lung Cancer</i> , 2015, 55, 53-58.	0.0	4
926	Identification of Genetic Mutations in Cancer: Challenge and Opportunity in the New Era of Targeted Therapy. <i>Frontiers in Oncology</i> , 2019, 9, 263.	1.3	62

#	ARTICLE	IF	CITATIONS
927	ALK and NSCLC: Targeted therapy with ALK inhibitors. F1000 Medicine Reports, 2011, 3, 21.	2.9	23
928	Long non-coding RNA RFPL3S is a novel prognostic biomarker in lung cancer. Oncology Letters, 2020, 20, 1270-1280.	0.8	4
929	Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer. Korean Journal of Internal Medicine, 2019, 34, 1116-1124.	0.7	6
930	Personalized targeted therapy in advanced non-small cell lung cancer. Cleveland Clinic Journal of Medicine, 2012, 79, S56-S60.	0.6	42
931	Molecular biology of lung cancer. Journal of Thoracic Disease, 2013, 5 Suppl 5, S479-90.	0.6	173
932	Pulmonary adenocarcinoma: implications of the recent advances in molecular biology, treatment and the IASLC/ATS/ERS classification. Journal of Thoracic Disease, 2014, 6, S502-25.	0.6	13
933	Switching off malignant pleural effusion formation-fantasy or future?. Journal of Thoracic Disease, 2015, 7, 1009-20.	0.6	15
934	Targeting EML4-ALK driven non-small cell lung cancer (NSCLC). Translational Lung Cancer Research, 2013, 2, 128-41.	1.3	16
935	ALK and ROS1 as a joint target for the treatment of lung cancer: a review. Translational Lung Cancer Research, 2013, 2, 72-86.	1.3	29
936	ALK and crizotinib: after the honeymoon what else? Resistance mechanisms and new therapies to overcome it. Translational Lung Cancer Research, 2014, 3, 250-61.	1.3	44
937	Expanding the portfolio of anti-ALK weapons. Translational Lung Cancer Research, 2015, 4, 5-7.	1.3	65
938	Ceritinib as a promising therapy for ALK related diseases. Translational Lung Cancer Research, 2014, 3, 376-8.	1.3	3
939	Targeted therapies in development for non-small cell lung cancer. Journal of Carcinogenesis, 2013, 12, 22.	2.5	67
940	Present Status and Problems on Molecular Targeted Therapy of Cancer. Cancer Research and Treatment, 2012, 44, 1-10.	1.3	24
941	Recent Advances in Molecular Targeted Therapy for advanced Colorectal Cancer and Non-Small Cell Lung Cancer. , 2012, 02, .		1
942	Epidermal growth factor receptor and K-Ras in non-small cell lung cancer-molecular pathways involved and targeted therapies. World Journal of Clinical Oncology, 2011, 2, 367.	0.9	39
943	Current and future treatment of anaplastic lymphoma kinase-rearranged cancer. World Journal of Clinical Oncology, 2015, 6, 104.	0.9	12
944	Is the determination of ctDNA a scientific "espy" that foresees cancer?. World Journal of Respiriology, 2017, 7, 35.	0.5	1

#	ARTICLE	IF	CITATIONS
945	Non-small cell lung cancer - genetic predictors. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2013, 157, 125-136.	0.2	34
946	Drug Resistance Mechanisms in Non-Small Cell Lung Carcinoma. Journal of Cancer Research Updates, 2013, 2, 265-282.	0.3	53
947	Nonâ€“Small Cell Lung Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2008, 6, 228.	2.3	343
948	LW1497, an Inhibitor of Malate Dehydrogenase, Suppresses TGF-Î²1-Induced Epithelial-Mesenchymal Transition in Lung Cancer Cells by Downregulating Slug. Antioxidants, 2021, 10, 1674.	2.2	4
949	Discovery of a Lung Cancer Oncogene, EML4-ALK, and Its Clinical Application. Japanese Journal of Lung Cancer, 2010, 50, 889-893.	0.0	0
951	Respiratory tract. , 2011, , 291-436.		1
952	Somatic Alterations and Targeted Therapy. , 2012, , 51-101.		0
953	Targeted Therapies for Non-small-Cell Lung Cancer. , 2012, , 93-114.		0
954	A Case of Adenocarcinoma of the Lung Successfully Treated with Pemetrexed as Fourth-line Chemotherapy for Multiple Liver Metastases After Acquired Resistance to Crizotinib. Japanese Journal of Lung Cancer, 2012, 52, 242-247.	0.0	0
955	Discovery of the EML4-ALK Fusion Oncogene; an Effective Target in Lung Cancer. Japanese Journal of Lung Cancer, 2012, 52, 136-141.	0.0	0
956	Knowing is Half the Battle in the Genetics of Acute Myelogenous Leukemia. Journal of Genetic Syndromes & Gene Therapy, 2012, 3, .	0.2	0
957	Molecularly Targeted Therapy: Past, Present and Future. Chemotherapy, 2012, 01, .	0.0	3
958	Oncogenic driver mutations. , 2012, , 45-58.		0
959	ALKimia : transmutaciones del cÃ¡ncer de pulmÃ³n.. Revista Colombiana De HematologÃ­a Y OncologÃ­a, 2012, 1, 46-58.	0.0	0
960	Crizotinib: A Breakthrough for Targeted Therapies in Lung Cance. Journal of the Advanced Practitioner in Oncology, 2012, 3, 267-72.	0.2	4
961	A New Paradigm for Personalized Medicine and Companion Diagnostics: The Contract Diagnostics Organization. The Open Conference Proceedings Journal, 2012, 3, 52-58.	0.6	0
963	Hsp90 Inhibitors in Clinic. RSC Drug Discovery Series, 2013, , 336-378.	0.2	0
964	TYPES OF DNA DAMAGE. , 2013, , 115-118.		0

#	ARTICLE	IF	CITATIONS
966	Molecular Testing in Pulmonary Tumors. , 2014, , 211-228.		0
967	Strategies in ALK Rearranged NSCLC Patients. , 2015, , 147-156.		0
968	Genomic Applications in Pulmonary Malignancies. , 2015, , 383-413.		0
969	Past and Current Developments in ALK-TKI Resistant NSCLC. Japanese Journal of Lung Cancer, 2015, 55, 936-940.	0.0	0
970	Chromosomal Translocations in Lung Cancer. , 2015, , 403-416.		0
971	Targeted Therapies for Non-Small Cell Lung Cancer. Current Clinical Pathology, 2015, , 89-101.	0.0	1
972	Resistance to crizotinib and therapeutic options. , 2015, , 51-59.		0
973	A cytological study of EML4-ALK mutations in lung cancer. The Journal of the Japanese Society of Clinical Cytology, 2015, 54, 187-191.	0.0	0
974	14. Molecular Target Therapy for Lung Cancer. The Journal of the Japanese Society of Internal Medicine, 2016, 105, 128b-129a.	0.0	0
975	Biomarkers for Lung Cancer: Focusing on Targeted Drug Resistance. Japanese Journal of Lung Cancer, 2016, 56, 55-60.	0.0	0
976	14. Molecular Target Therapy for Lung Cancer. The Journal of the Japanese Society of Internal Medicine, 2016, 105, 1840-1848.	0.0	0
977	Chirurgie von primären Lungentumoren bei alten Patienten. , 2016, , 211-222.		0
979	Strategies for power calculations in predictive biomarker studies in survival data. Oncotarget, 2016, 7, 80373-80381.	0.8	4
981	Cell Proliferation and Differentiation. , 2017, , 11-35.		0
982	Accurate Nodal Staging and Biomarker Testing with Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration. , 2017, , 79-96.		0
983	Treatment After Crizotinib Resistance in ALK+ Non-Small-Cell Lung Cancer. UHOD - Uluslararası Hematoloji-Onkoloji Dergisi, 2017, 27, 60-68.	0.1	0
984	Translocations as Predictive Biomarkers in Lung Cancer. Molecular Pathology Library, 2018, , 159-171.	0.1	0
986	Mechanisms of Acquired Resistance to Targeted Therapy in NSCLC: Role of Repeat Biopsy and Nursing Considerations. , 2019, , 51-64.		0

#	ARTICLE	IF	CITATIONS
987	EML4-ALK V3 Drives Cell Migration Through NEK9 and NEK7 Kinases in Non-Small-Cell Lung Cancer. SSRN Electronic Journal, 0, , .	0.4	0
988	Anaplastic Lymphoma Kinase. Current Cancer Research, 2019, , 31-54.	0.2	0
992	Malignant Epithelial Tumors of the Lung. , 2020, , 317-400.		0
993	Personalized Management of Cancers of Various Organs/Systems. , 2021, , 509-602.		0
995	Resistance to anaplastic lymphoma kinase inhibitors: knowing the enemy is half the battle won. Translational Lung Cancer Research, 2020, 9, 2545-2556.	1.3	13
996	Incorporating Circulating Biomarkers into Clinical Trials. , 2020, , 233-247.		0
997	Pharmacogenomics of Antitumor Targeted Agent and Immunotherapy. , 2020, , 55-82.		0
998	Utilidad clnica de la biopsia lquida para el diagnstico y seguimiento de los pacientes con CPNM y <i>EML4-ALK</i>. Advances in Laboratory Medicine / Avances En Medicina De Laboratorio, 2020, 1, .	0.1	0
1000	Achievements in targeted therapies. , 0, , 215-233.		0
1001	Alectinib in the treatment of advanced ALK + NSCLC. Onkologie (Czech Republic), 2020, 14, 135-138.	0.0	0
1003	Bosutinib reduces the efficacy of Dasatinib in triple-negative breast cancer cell lines. Anticancer Research, 2014, 34, 1629-35.	0.5	7
1004	ALK inhibitors in non-small cell lung cancer: crizotinib and beyond. Clinical Advances in Hematology and Oncology, 2014, 12, 429-39.	0.3	179
1005	MYC-xing it up with PIK3CA mutation and resistance to PI3K inhibitors: summit of two giants in breast cancers. American Journal of Cancer Research, 2015, 5, 1-19.	1.4	29
1006	Overview of clinicopathologic features of ALK-rearranged lung adenocarcinoma and current diagnostic testing for ALK rearrangement. Translational Lung Cancer Research, 2015, 4, 149-55.	1.3	21
1007	Progress of EGFR-TKI and ALK/ROS1 inhibitors in advanced non-small cell lung cancer. International Journal of Clinical and Experimental Medicine, 2015, 8, 10330-9.	1.3	19
1008	Establishment and application of a multiplex genetic mutation-detection method of lung cancer based on MassARRAY platform. Cancer Biology and Medicine, 2016, 13, 68-76.	1.4	4
1023	CDRgator: An Integrative Navigator of Cancer Drug Resistance Gene Signatures. Molecules and Cells, 2019, 42, 237-244.	1.0	2
1025	Resistance to Targeted Agents Used to Treat Paediatric ALK-Positive ALCL. Cancers, 2021, 13, 6003.	1.7	6

#	ARTICLE	IF	CITATIONS
1026	Genetic fusions favor tumorigenesis through degron loss in oncogenes. <i>Nature Communications</i> , 2021, 12, 6704.	5.8	14
1027	The impact of the <i>ALK</i> fusion variant on clinical outcomes in <i>EML4-ALK</i> patients with NSCLC: a systematic review and meta-analysis. <i>Future Oncology</i> , 2022, 18, 385-402.	1.1	7
1028	Utility of the Ba/F3 cell system for exploring on-target mechanisms of resistance to targeted therapies for lung cancer. <i>Cancer Science</i> , 2022, 113, 815-827.	1.7	11
1030	Development of a degrader against oncogenic fusion protein FGFR3-TACC3. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2022, 60, 128584.	1.0	5
1031	Efficacy and safety exposure-response analyses of entrectinib in patients with advanced or metastatic solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 363-372.	1.1	4
1032	Holistic View of ALK TKI Resistance in ALK-Positive Anaplastic Large Cell Lymphoma. <i>Frontiers in Oncology</i> , 2022, 12, 815654.	1.3	3
1034	Durable Clinical Response to ALK Tyrosine Kinase Inhibitors in Epithelioid Inflammatory Myofibroblastic Sarcoma Harboring PRRC2B-ALK Rearrangement: A Case Report. <i>Frontiers in Oncology</i> , 2022, 12, 761558.	1.3	17
1035	Single-cell gene fusion detection by scFusion. <i>Nature Communications</i> , 2022, 13, 1084.	5.8	8
1036	Custom multi-tumor next-generation sequencing panel for routine molecular diagnosis of solid tumors: Validation and results from three-year clinical use. <i>International Journal of Molecular Medicine</i> , 2022, 49, .	1.8	2
1037	Targeting ALK Rearrangements in NSCLC: Current State of the Art. <i>Frontiers in Oncology</i> , 2022, 12, 863461.	1.3	15
1038	A Model for Lung Cancer Prediction. , 2021, , .		0
1039	Therapeutic advances in non-small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy. <i>MedComm</i> , 2021, 2, 692-729.	3.1	38
1040	Role of <i>STK11</i> in <i>ALK</i> -positive non-small cell lung cancer (Review). <i>Oncology Letters</i> , 2022, 23, 181.	0.8	2
1065	Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 497-530.	2.3	530
1066	The Impact of Comprehensive Genomic Profiling (CGP) on the Decision-Making Process in the Treatment of ALK-Rearranged Advanced Non-Small Cell Lung Cancer (aNSCLC) After Failure of 2nd/3rd-Generation ALK Tyrosine Kinase Inhibitors (TKIs). <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	2
1067	Impact of compound mutations I1171N and F1174I and I1171N and L1198H on the structure of ALK in NSCLC pathogenesis: atomistic insights. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 4735-4743.	2.0	6
1069	PROTACs: great opportunities for academia and industry (an update from 2020 to 2021). <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	77
1070	Triclosan and β -bisabolol-loaded nanocapsule functionalized with ascorbic acid as a dry powder formulation against A549 lung cancer cells. <i>Journal of Drug Delivery Science and Technology</i> , 2022, 74, 103463.	1.4	0

#	ARTICLE	IF	CITATIONS
1071	<i>LINC00116</i> Is a Novel Prognostic Biomarker of Nonsmall Cell Lung Cancer. <i>Genetic Testing and Molecular Biomarkers</i> , 2022, 26, 340-347.	0.3	0
1072	Molecular biomarkers and liquid biopsies in lung cancer. <i>Seminars in Oncology</i> , 2022, 49, 275-284.	0.8	2
1073	3D-QSAR and Docking Studies on Pyrimidine Derivatives of Second-Generation ALK Inhibitors. <i>Pharmaceutical Fronts</i> , 0, .	0.4	0
1074	Fibroblast growth factor receptor 3 overexpression mediates <i>ALK</i> inhibitor resistance in <i>ALK</i> -rearranged non-small cell lung cancer. <i>Cancer Science</i> , 2022, 113, 3888-3900.	1.7	8
1075	Characterization of the cholangiocarcinoma drug pemigatinib against FGFR gatekeeper mutants. <i>Communications Chemistry</i> , 2022, 5, .	2.0	10
1076	Durable clinical response to ALK tyrosine kinase inhibitors in ALK-rearranged non-small cell lung cancer: a case report. <i>Translational Cancer Research</i> , 2022, 11, 2967-2972.	0.4	2
1077	Prediction of Resistance Mutations Against Upcoming Anaplastic Lymphoma Kinase Inhibitors. <i>Targeted Oncology</i> , 2022, 17, 695-707.	1.7	4
1078	Discovery of a potent EGFR and ALK dual mutation inhibitor containing N-(3-((4-(2-(cyclopropylsulfinyl)phenyl)amino)pyrimidin-2-yl)amino)phenyl)acrylamide scaffold. <i>Bioorganic Chemistry</i> , 2022, 129, 106188.	2.0	3
1079	Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance. <i>Cancer Discovery</i> , 2023, 13, 170-193.	7.7	6
1080	Targeting Gatekeeper Mutations for Kinase Drug Discovery. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 15540-15558.	2.9	14
1081	Primary resistance to first- and second-generation ALK inhibitors in a non-small cell lung cancer patient with coexisting ALK rearrangement and an ALK F1174L-cis-S1189C de novo mutation: A case report. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	1
1083	Silibinin Overcomes EMT-Driven Lung Cancer Resistance to New-Generation ALK Inhibitors. <i>Cancers</i> , 2022, 14, 6101.	1.7	4
1084	Hallmarks of Anaplastic Lymphoma Kinase Inhibitors with Its Quick Emergence of Drug Resistance. <i>Pharmaceutical Fronts</i> , 0, .	0.4	0
1085	Recent Updates on Structural Aspects of ALK Inhibitors as an Anticancer Agent. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2023, 23, 900-921.	0.9	1
1086	MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations. , 2023, , 29-34.		0
1087	Transcriptome analysis and identification of genes associated with leaf crude protein content in foxtail millet [<i>Setaria italica</i> (L.) P. Beauv.]. <i>Frontiers in Genetics</i> , 0, 14, .	1.1	0
1089	Successful Treatment with Crizotinib to Overcome Drug Resistance Possibly Due to <i>Mesenchymal-epithelial Transition</i> ; Amplification in a Lung Cancer Patient with the <i>Echinoderm Microtubule-associated Protein-like 4-anaplastic Lymphoma Kinase</i> Fusion Gene. <i>Internal Medicine</i> , 2023, , .	0.3	2
1091	First-line crizotinib therapy is effective for a novel SEC31A-anaplastic lymphoma kinase fusion in a patient with stage IV lung adenocarcinoma: a case report and literature reviews. <i>Anti-Cancer Drugs</i> , 2023, 34, 294-301.	0.7	0

#	ARTICLE	IF	CITATIONS
1092	ALK-positive lung cancer: a moving target. <i>Nature Cancer</i> , 2023, 4, 330-343.	5.7	24
1093	Treatment of advanced non-small cell lung cancer with driver mutations: current applications and future directions. <i>Frontiers of Medicine</i> , 2023, 17, 18-42.	1.5	8
1094	Synthesis and evaluation of sulfonamide derivatives targeting EGFR790M/L858R mutations and ALK rearrangement as anticancer agents. <i>Bioorganic and Medicinal Chemistry</i> , 2023, 85, 117241.	1.4	1
1095	Molecular Anatomy of the EML4-ALK Fusion Protein for the Development of Novel Anticancer Drugs. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5821.	1.8	3
1096	Target Hyperactive ERK Signaling for Cancer Therapy. , 2023, , 1-39.		0
1097	Iruplalkib (WXâ€™0593), a novel ALK/ROS1 inhibitor, overcomes crizotinib resistance in preclinical models for non-small cell lung cancer. <i>Investigational New Drugs</i> , 2023, 41, 254-266.	1.2	6
1103	Targeted Therapy and Personalized Medicine. <i>Cancer Treatment and Research</i> , 2023, , 177-205.	0.2	2
1107	Case report: ALK D1225N missense mutation in lung adenocarcinoma responds to tyrosine kinase inhibitors. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	1
1110	Molecular testing in lung cancer. , 2024, , 319-337.		0
1114	Tumor Inflammatory Microenvironment in Lung Cancer: Heterogeneity and Implications. , 2023, , 1-19.		0
1116	Case report: ALK-positive histiocytosis presented as bilateral synchronous breast masses with long-term remission on crizotinib. <i>Frontiers in Medicine</i> , 0, 10, .	1.2	0